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Abstract 
Ferreira M., 2017. Multifunctional nanoparticles for targeted drug delivery and 
imaging to the ischemic heart 
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 Currently, there is no major discovery of an effective cure to restore the function of an 
injured heart, despite of the existing and developeing therapies. While existing options 
ameliorate the care of myocardial infarction (MI) and heart failure patients, cardiac stem cell 
therapy has only recently shown positive results in clinical trials, and thus there is an urgent 
medical need to develop advanced therapeutic entities to reverse this disease burden. The 
employment of biomaterials as potential therapeutics for MI is at the pre-clinical stage. 
Particulate systems are arising as a promising tool to provide minimally invasive treatment, an 
important aspect to take into account for clinical translation and patient compliance. 
 Porous silicon (PSi) and spermine-acetalated dextran (AcDXSp) are emerging 
biomaterials for applications in varying biomedical fields. Drug delivery is one of these fields 
benefiting from the materials’ properties, such as biocompatibility, biodegradability, 
customized particle preparation, surface functionalization, simple yet efficient drug loading, 
and tunable release of the therapeutic cargos. Therefore, the aim of this thesis was to develop 
multifunctional PSi and AcDXSp platforms for targeted drug delivery to and imaging of the 
ischemic heart. Initially, the biocompatibility of PSi-based carriers of different sizes and 
surface chemistries was evaluated. Thermally hydrocarbonized PSi microparticles and 
thermally oxidized PSi nanoparticles showed better cytocompatibility in vitro, while in vivo, 
the thermally hydrocarbonized PSi microparticles activated pro-inflammatory and pro-fibrotic 
genes. However, all the particles showed no alterations in the cardiac function in both healthy 
and MI rats. Secondly, three different PSi-based nanosystems were developed, functionalized 
with a metal chelator for radiolabeling and three different peptides (atrial natriuretic peptide 
(ANP) and two other heart-homing peptides), with the aim to screen the targetability of the 
nanoparticles to the ischemic heart. All the nanosystems showed no toxicity up to 50 μg/mL 
concentration, and cell–nanoparticle interaction studies in cardiomyocytes and non-myocytes 
revealed a preferential cellular interaction with ANP-functionalized nanoparticles in both the 
cell types, through the natriuretic peptide receptors (NPRs) present at the cell surface. Thirdly, 
the ANP-PSi functionalized nanoparticles were PEGylated in order to improve the colloidal 
stability and enhance the circulation time, in isotonic 5.4% glucose solution and in human 
plasma. Upon labeling with radioisotope Indium-111, the ANP-PSi nanoparticles displayed a 
preferential accumulation and selectivity towards the endocardial layer of the ischemic heart. 
In vivo delivery of a cardioprotective small drug molecule from the ANP-PSi showed 
attenuation of the extracellular signal-regulated kinase pathway that is involved in the 
hypertrophic signaling of the injured heart. Lastly, and in parallel, the development of 
functionalized and dual-loaded AcDXSp nanoparticles for potential application in cellular 
reprogramming was proven successful, by utilizing acidic pH-triggered drug delivery of the two 
poorly water-soluble cargos. The incubation of non-myocytes with ANP-functionalized 
AcDXSp nanoparticles showed therapeutic modulation of key signaling pathways involved in 
the direct fibroblast reprogramming into cardiomyocytes. Overall, PSi and AcDXSp-based 
(nano)particulate systems were developed, bringing new insights about potential therapeutic 
advances in the applicability of imaging and targeted delivery of relevant pharmacological 
molecules to the ischemic heart with a minimally invasive therapeutic approach. 
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TCPSi  Thermally carbonized porous silicon 
TEA  Triethylamine 
TEM  Transmission electron microscopy 
TFA  Trifluoroacetic acid 
TGF-β  Transforming growth factor beta 
TH   Thermal hydrocarbonization 
THCPSi  Thermally hydrocarbonized porous silicon 
TIPS  Triisopropylsilane 
TNF-α  Tumor necrosis factor-α  
TO   Thermal oxidation 
TOPSi  Thermally oxidized porous silicon  
Un-D  UnTHCPSi-DOTA 
Un-D-ANP UnTHCPSi-DOTA-ANP 
Un-D-P2  UnTHCPSi-DOTA-P2 
Un-D-P3  UnTHCPSi-DOTA-P3 
Un-P  UnTHCPSi-PEG 
Un-P-D  UnTHCPSi-PEG-DOTA 
Un-P-D-ANP UnTHCPSi-PEG-DOTA-ANP 
UnTHCPSi Undecylenic acid modified THCPSi 
w/o/w  water-in-oil-in-water  
α-SMA  Alpha smooth muscle actin 
?-potential  Zeta-potential 
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1. Introduction 
Cardiovascular diseases (CVD) cause the highest mortality rates globally, and over one-
third of the CVD-related casualties are due to the ischemic heart disease (IHD).1, 2 Because IHD 
causes injury to the myocardium, and the heart has extremely limited capacity to recover from 
the ischemic insult,3 the progress of the initial ischemic event – myocardial infarction (MI) – 
leads to a decompensated state characterized by scar formation, ventricular wall dilation, 
thinning and hypertrophy.4-6 This pathological state – heart failure – is irreversible, having no 
cure up to date. While the currently available therapeutics do not perform towards curing the 
disease, but rather treat the symptoms and/or try to stop the progression of the disease, they 
only provide a certain improvement in the state of care of heart failure patients. Therefore, 
there is an unmet need to find a permanent solution for these patients.  
The understanding of the basic mechanisms that lead to the development and 
progression towards heart failure has emphasized the vast complexity of the molecular and 
cellular mechanisms that govern the pathological process of this disease and, over time, more 
and more of this puzzle is uncovered. The clarification about the characteristic pathological 
processes of heart failure leads to the identification of new therapeutic targets.7 Alternatively 
to the pharmacological medicines and implantable devices available in the clinic for heart 
failure patients, other therapeutic approaches are currently being investigated and developed. 
To name a few, cell therapy, cardiac tissue engineering and particulate systems have been 
increasingly studied to tackle the problematic of cardioprotection and cardio restoration that 
the current therapies lack.8-11 
While pharmacological medication may be administered orally or intravenously, 
implantable devices require risky surgical procedures that many times put the lives of patients 
at stake. In both cases, the benefits are temporary and only amelioration of the patients quality 
of life is achieved. For newly developing therapeutics strategies, such as cell therapy or cardiac 
tissue engineering, the administration routes required are always highly invasive.12, 13 Ideally, 
intravenous (i.v.) or oral administration routes are preferred for patient compliance and are 
regarded as an important factor to take into account when considering clinical translation.14 
Thus, nanoparticulate systems are more suitable for administration by minimally invasive 
routes, such as the i.v. route. Besides the advantageous possibility of i.v. administration, 
nanocarriers are versatile platforms for the creation of functional nanosystems. This is due to 
their tunable properties, which are for example dictated by the type of material, size, surface 
chemistry, porosity, or surface area. This brings up the possibility to deliver one or more 
payloads with similar or different physicochemical properties, allowing the creation of 
functional carriers for specific targeting, stimuli responsiveness, imaging or more than one 
feature in the same nanocarrier, leading to versatile applications in different pathologies.15, 16 
Porous silicon (PSi) and acetalated dextran (AcDX) are two of the many different 
examples of biomaterials available for the production and development of nanoparticulate 
systems. On one hand, PSi materials have been widely studied for different applications in the 
biomedical field, due to their attractive properties, such as tunable porosity and surface 
chemistry, stability, high surface area, biocompatibility, and biodegradability.17-30 On the other 
hand, AcDX tackles some problems of PSi materials, such as the leakage of cargos, as the 
polymeric matrix only allows drug release below certain pH values, featuring a triggered cargo 
release upon exposition to an acidic pH stimulus.31 Thus, there exists evident potential for both 
the biomaterials with increasing interest to be explored for new applications for these 
biomaterials, such as the treatment of MI and heart failure. 
This thesis project began by investigating the biocompatibility of different surface 
chemistries and sizes of PSi-based particles, a biomaterial that had not been employed for MI 
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therapy before. Upon favorable biocompatibility features, the surface functionalization of the 
PSi nanoparticulate systems was done with a metal chelator for radiolabeling purposes, 
followed by attachment of different heart-homing peptides to enhance therapeutic efficacy. 
Next, the different nanosystems developed were screened to find out the most promising 
nanosystem(s) for targeted drug delivery and imaging, and for clarification of the mechanism 
of the cell–nanoparticle interactions. Additional stability protection was provided by coating 
the most promising nanosystem with polyethylene glycol (PEG), followed by detailed in vivo 
characterization and evaluation of the biodistribution and heart accumulation. In addition, 
proof-of-concept studies of the potential bioeffect upon delivery of a cardioprotective 
compound to MI diseased hearts were investigated. In parallel, the polymeric nanocarrier 
(AcDX) was investigated for the ability to deliver two relevant pharmacological small 
molecules, involved in the direct cellular reprogramming of fibroblasts to cardiomyocytes, with 
similar physicochemical properties in a pH-dependent fashion, for combination drug therapy. 
The release of the two drugs was evaluated in physiologically relevant environments, such as 
the intracellular acidic (pH 5) and the extracellular (pH 7.4) compartments. Furthermore, the 
in vitro drug delivery and biological effects of the developed functionalized nanoparticles were 
assessed, for further application in the direct pharmacological reprogramming of cardiac 
fibroblasts.  
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2. Literature overview 
2.1. Ischemic heart diseases and therapeutic approaches 
 
2.1.1. Cardiovascular diseases 
 
Cardiovascular diseases (CVD) are characterized by a group of disorders of the heart 
and blood vessels, including hypertension, coronary heart disease, cerebrovascular disease, 
peripheral vascular disease, heart failure, rheumatic heart disease, congenital heart disease, 
and cardiomyopathies, according to the World Health Organization.2 They are mainly the 
result of improved public health measures over the 20th century, shifting from causing less than 
10% of deaths in the early 1900’s to the reality of becoming the leading cause of death, and a 
great economic and resource burden on public health systems in the present days.32-34 Official 
reports state that CVD are the number 1 cause of death globally, which in 2015 represented 17.7 
million casualties (31% of all global deaths) caused by some form of CVD. Out of this colossal 
number, 7.4 million deaths were due to coronary heart disease, causing 1 out of 6 deaths in the 
USA in 2010.34, 35 The 5-year survival rate for heart failure patients is disturbing, worse than 
for most cancer patients. Remarkably, the costs of care exceed US$30 billion per year in the 
United States.36 In Europe, CVD cause 3.9 million deaths each year. The number of existing 
cases is astonishing, more than 85 million people live with this burden and about 11.3 million 
new cases of CVD arose in 2015. The overall costs of CVD to the European Union economy are 
estimated as €210 billion a year.35 In Finland, ischemic heart diseases (IHD) are still a major 
cause of death, despite a substantial decrease over the years. IHDs caused 1 out of 5 deaths in 
Finland in the year 2014.37  
 
  
2.1.1.1. The heart and its cellular composition 
 
The heart is a structurally complex organ divided into four chambers, namely two atria 
and two ventricles. The right atrium and right ventricle pump venous blood to the pulmonary 
circulation to be oxygenated. When returning to the heart, oxygenated blood enters the left 
atrium and is pumped out to the systemic circulation by the left ventricle (LV). While the atria 
are characterized by a thin wall and function as large reservoir conduits of blood for their 
respective ventricles, the ventricles in turn act as pumping agents for the propulsion of blood.38 
Figure 1 shows a simplified anatomical structure of the heart. 
The heart architecture is composed of cell types of different features, which contribute 
to the heart structure, as well as for the mechanical, biochemical and electrical properties. The 
three main cardiac cell types with respect to the number of cells are cardiomyocytes, 
endothelial cells (forming the endocardium, the interior of blood vessels and cardiac valves), 
and fibroblasts. With regards to the relative numbers, the cell counts differ substantially and 
depend not only on the species, age, and gender but also on, for example, the lack of a unique 
and comprehensive marker for fibroblasts, hindering the precision analysis of the cardiac cell 
types and relative abundances, as fibroblasts are composed of heterogeneous cell 
populations.39, 40 For this reason, several publications have listed fibroblasts as one of the most 
abundant cardiac cells.39-42 Yet, recent reports acknowledge endothelial cells and 
cardiomyocytes as the most abundant cell types in adult murine and human hearts, followed 
by fibroblasts.5, 43 Other important cell groups are the smooth muscle cells, epicardial cells, and 
the electrical impulse conductors, pacemaker cells and Purkinje fibers (Figure 1).3 All the 
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cardiac cells work harmoniously to allow the heart to do its job: to provide a continuous blood 
circulation to the whole body.  
 
 
 
Figure 1. The heart structure and its constitutive cardiac cell types. Copyright © 2013 Nature 
Publishing Group. Abbreviations: AVN, atrioventricular node; SAN, sinoatrial node. Adapted 
with permission from ref.3. 
 
 
2.1.1.2.  Myocardial infarction and hypertrophic signaling 
 
Myocardial infarction (MI) is defined by the loss of viable cardiomyocytes in response 
to a prolonged shortage in blood supply in the heart muscle, causing a deprivation of oxygen 
and glucose needed for cellular metabolism. MI can be the manifestation of coronary artery 
disease for the first time, or occur repeatedly in patients with established disease.44 Upon an 
ischemic event, the development of histological cell death begins as early as in 20 min,45 and 
complete necrosis may be identified after 2–4 h, or even longer, after the onset of MI. This 
depends on several factors, such as the existence/abundance of collateral blood circulation in 
the ischemic area, individual oxygen and nutrient demands, the application of preconditioning 
(where repetitive short episodes of ischemia protect the myocardium against a later ischemic 
insult), sensitivity of the myocytes to ischemia, and permanent or intermittent occlusion of the 
coronary artery.46 In particular, the LV wall encompasses three different layers that include the 
endocardial layer (inner oblique), myocardium (middle circular) and the epicardial layer 
(outer oblique), which translate into differences in the deformation and function patterns 
across the LV wall. In systole, the endocardial layer is subjected to greater straining 
dimentional deformations than any other transmural layer of the LV, having a major 
contribution to the the heart function. However, in MI, this inner oblique layer is the most 
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vulnerable and the first affected area upon an insult caused by ischemia,47 characterized by 
evident morphologic and functional changes, leading to a detrimental function of the heart.48  
In response to an ischemic insult and consequent increase in loading conditions and 
ventricular wall stress, the heart will develop reparative phenotypic alterations, triggering a 
cascade of biochemical intracellular signaling processes. The initial post-MI phase of LV 
remodeling results from fibrotic repair of the necrotic area with collagen scar formation, 
elongation, and thinning of the infarcted zone. This is an adaptive attempt of the heart to 
normalize the stroke volume and cardiac output.49 Due to wall stress, this early adaptation can 
progress into a decompensated state with deep changes in gene expression, contractile 
dysfunction, and extracellular remodeling.50, 51  
In addition, the remodeling process is also driven by myocyte hypertrophic 
enlargement in the non-infarcted areas, resulting in an overall increased wall mass, ventricular 
dilation and shape adjustment towards spherical chamber configuration.52, 53 LV remodeling 
may last for several weeks or months, and will depend, among others, on the size, location, 
transmural extent of the infarct, and/or local trophic factors.54 This remodeling results in 
progressive deterioration of ventricular performance and can ultimately lead to heart failure 
(Figure 2).55, 56 
 
 
 
 
Figure 2. Schematic representation of post-myocardial infarction left ventricular remodeling. 
The early phase is characterized by thinning and elongation of the fibrous scar within the 
infarcted zone. Subsequent LV dilation, with a transition from an elliptical to a more spherical 
configuration, is driven essentially by diffuse myocyte hypertrophy associated with increased 
apoptosis (not shown) and increases in interstitial collagen. Copyright © 2011 American 
College of Cardiology Foundation, Elsevier Inc. Reprinted with permission from ref.56. 
 
 
Hypertrophic signaling is heavily influenced and stimulated by ventricular wall 
distress. Many transcriptional and growth factors are upregulated in hypertrophy and serve as 
potential therapeutic targets. Among them, this thesis gives emphasis to the extracellular 
signal–regulated kinases (ERK) from the mitogen-activated protein kinase (MAPK) family as 
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a therapeutic target and natriuretic peptides (in particular, atrial natriuretic peptide (ANP)) as 
a potential targeting moiety. 
  
Cardiac hypertrophy and ERK1/2 pathway as a therapeutic target 
 
ERK 1/2 belongs to one of the 4 MAPK subfamilies and has important roles in heart 
development and pathological processes, such as hypertrophy, cardioprotection vs. myocardial 
cell death, or other cardiac remodeling events, including chamber dilation, fibrosis, and 
changes in structural proteins and ion channels.57 ERK 1/2 hypertrophic signaling is 
characterized by phosphorylation of the ERK 1/2 protein, which in turn activates transcription 
factors in the nucleus and leads to the hypertrophied phenotype of cardiomyocytes.58 Previous 
reports have shown the involvement of ERK pathway with hypertrophy in the myocardium.59-
62 For example, Bueno et al.62 demonstrated that MAPK kinase-1 (or MEK1) transgenic mice 
with established concentric hypertrophy and MEK1 adenovirus-infected neonatal 
cardiomyocytes had ERK1/2 activation, revealing that the MEK1–ERK1/2 signaling pathway 
is involved in hypertrophy. Thus, the observation that the inhibition of ERK 1/2 pathway 
attenuates hypertrophy and makes researchers believe that this could constitute a therapeutic 
target. Peng et al.63 observed that angiotensin II and epidermal growth factor (EGF) increase 
the phosphorylation of ERK and lead to hypertrophy in myoblastic H9c2 cells. By using 
pharmacological inhibitors and gene silencing, they observed decreased phosphorylation of 
ERK, demonstrating a protective effect of these therapeutics against hypertrophy induced by 
angiotensin II.63 Another study supported the use of peptides to inhibit Ca2+/calmodulin 
protein kinase II to reduce cardiac hypertrophy both in in vitro and in vivo models, with the 
observation of significantly reduced ERK phosphorylation.64 Thus, exploring the possibility of 
reducing the phosphorylation of ERK in vivo using heart-targeted nanoparticles is one of the 
aims of this thesis. 
  
 
Natriuretic peptides and natriuretic peptide receptors 
 
 Natriuretic peptides are circulating hormones produced mainly in the heart. In 
humans, the natriuretic family consists of atrial natriuretic peptide (ANP), brain natriuretic 
peptide (BNP), and C-type natriuretic peptides.65-67 Natriuretic peptides have a pivotal role in 
the regulation of intravascular plasma volume, fluid retention, and vascular tonicity, by 
increasing renal excretion of salt and water, vasodilation, and vascular permeability.68-70 
Moreover, ANP has been demonstrated to have a paracrine role in the regulation of fibroblast 
growth and mitogenesis during cardiac hypertrophy,71 cardioprotective properties, 
antiapoptotic effects, and inhibited hypertrophy of cardiomyocytes.72 In the event of MI and in 
heart failure, the plasma levels of ANP and BNP are significantly elevated, and their 
upregulation takes place during hypertrophy.73-75 In particular, studies suggest that the 
expression of both ANP and BNP are increased in hypertrophy, in the margins of the infarcted 
zone of the LV, and ANP was particularly produced in the fibroblasts that invaded the infarcted 
myocardium and along with their transition to myofibroblasts.76 Therefore, the detection of 
ANP and BNP serum levels is currently used as a biomarker in the diagnostics and prognostics 
of hypertrophy and heart failure.75, 77, 78 
 Natriuretic peptide actions are mediated by natriuretic peptide receptors (NPR), in 
particular, the NPR-A or guanylyl cyclase-A, and the NPR-B. There is a third NPR, responsible 
for the clearance natriuretic peptides, the NPR-C. ANP is a ligand for the NPR-A, exerting its 
known natriuretic effects by catalyzing the synthesis of cyclic guanosine monophosphate 
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(cGMP). ANP also binds to the clearance NPR-C, being cleared from the extracellular 
environment through receptor-mediated internalization and degradation.79 This receptor, 
together with neutral endopeptidases, is responsible for the very short half-life of ANP (1.7–
3.1 min) (Figure 3).80-83 Although NPR-A is widely expressed in different organs, such as 
lungs, kidney, adrenal gland, brain, testis and vascular smooth muscle tissue, it has been 
described to be expressed in several regions of the heart. NPR-C is also reported to be 
expressed in the endocardium of primate hearts and in rat hearts.84, 85 In humans, NPR-A 
mRNA is present in the LV, while NPR-C has an even distribution in both the ventricles.86 At 
the cellular level, both NPR-A and NPR-C are present in cardiac cells. Cardiac fibroblasts seem 
to express all NPR, but predominantly the NPR-C (approximately 80%), while all NPR are 
observed for cardiomyocytes, although the most significant NPRs were predominantly NPR-A 
and possibly NPR-C.71, 85  
 Based on the presence of NPR-A and NPR-C in cardiac cells, in this thesis, it was 
explored the possibility of homing drugs inside nanoparticles into the cardiac cells and the 
heart using the ANP peptide as a targeting moiety. 
 
Figure 3. The three main types of natriuretic peptides and the NPRs. Reprinted with 
permission from ref. 87. 
 
 
2.1.1.3.  Small animal models for myocardial ischemia 
 
Animal models of MI are necessary to validate the finding on in vitro cell models, 
providing a better understanding of the pathological mechanisms of the disease. In addition, 
they serve as tools for investigation of possible therapeutic interventions and are useful for 
studying the biodistribution and bioeffects of drug delivery systems (DDS) in a real context. In 
the case of small animal models, such as rodents and rabbits, the most common methods to 
induce MI are either by the left anterior descending artery (LAD) surgical ligation, genetic 
modifications (for mice), and chemical induction.88 In this thesis, both LAD and chemically 
induced MI in rodent models were used. 
LAD ligation is the most used surgical induction of acute MI by blocking the LAD either 
permanently or for a limited amount of time.89 Infarctions can be induced by ligating different 
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regions of the coronary artery and provide a localized, although with variable sizes, infarction 
in the LV.90 In addition, the use of catecholamines, such as isoprenaline, (?-receptor adrenergic 
agonist) is a well-established non-surgical method to induce MI chemically in animal models 
like rats.91 This model is more advantageous than the LAD model due to the fewer mortality 
rates of animals. It has been reported that the hearts of isoprenaline MI animal models display 
a rise in cardiac marker enzymes, and metabolic and morphologic abnormalities similar to 
those observed in human MI, as it causes severe stress and produces necrosis in the ventricular 
subendocardial region and the inter-ventricular septum.92, 93 Isoprenaline induces acute 
diffuse myocyte damage upon a single subcutaneous or intraperitoneal injection. The principle 
of injury is based on the infliction of alterations in intracellular Ca2+ leakage, due to 
hyperphosphorylation of the ryanodine receptor 2 of the sarcoplasmic reticulum.94 The acute 
increased levels of isoprenaline are cardiotoxic, leading to significant myocyte loss and 
hypertrophy in the long term.95-97 Both animal models are widely used in the assessment of the 
therapeutic cardioprotective potential of natural and synthetic entities.88, 98, 99 
 
 
2.1.2. Treatment of myocardial infarction and heart failure 
 
2.1.2.1.  Current therapeutics 
 
The LV remodeling is closely related to the activation of a series of upregulated factors 
after MI, hemodynamic imbalance and augmented LV wall stress. Paracrine, neuroendocrine, 
and autocrine factors include the adrenergic nervous system, renin-angiotensin-aldosterone 
axis, increased oxidative stress, as well as pro-inflammatory cytokines and endothelin-1.56 
Thus, the current therapeutic interventions for MI patients mainly attempt to prevent 
recurrent ischemic events, reduce congestion, delay pathological remodeling, and preserve 
myocardial contractile function by maintaining myocyte viability.100 At present, the 
therapeutic options clinically available for MI patients only ameliorate their survival, care, and 
thus, the prevalence of the disease.101 To date, no cure has been found for this burden. The 
main therapies for MI include changes in the lifestyle, reduction of afterload, and ?-adrenergic 
and renin–angiotensin–aldosterone blockage. For patients with advanced disease, the use of 
mechanical support devices is considered and, ultimately, heart transplantation.55, 102 A brief 
list of the currently used pharmacological groups 99 and implantable heart devices/surgical 
procedures 103, 104 are summarized in Table 1. 
 
Table 1. Pharmacological therapeutic approaches and surgically implantable devices used 
for the therapy of MI and heart failure. 
 
Pharmacological therapy Surgically implantable devices Refs. 
Angiotensin-converting enzyme inhibitors 
Angiotensin-receptor blockers 
?-blockers 
Mineralocorticoid-receptor antagonists 
Ivabradine 
Diuretics 
Digoxin 
Hydralazine, Isosorbide dinitrate 
Ventricular assist devices 
Pacemakers (cardiac resynchronization 
therapy) 
Cardioverter-defibrillators 
Coronary artery bypass 
Angioplasty 
Stent 
 
 
 
55, 101-104 
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2.1.2.2. Therapeutics under development 
 
 As the existing therapeutic options do not stop the high mortality rates and morbidity 
of heart failure, this complex pathology is now actively investigated, in order to better 
understand the pathophysiological mechanisms, as well as to discover new therapeutic targets 
and approaches for the prevention of remodeling or at least improvement of patient care. 
Different therapeutic approaches are investigated, either for cardioprotective or cardio 
restorative purposes, leading to the development of most diverse strategies to tackle the burden 
of heart failure.105 Discovery and use of small drug molecules and biologics, gene therapy, cell 
therapy, tissue engineering, particulate systems, or a combination of them are the main 
research considerations of today.  
 Cardiac regeneration provides new hope for the treatment and cure of heart failure. 
While zebrafish heart can fully regenerate after amputation of the heart apex, the mammalian 
adult heart has limited regenerative potential,106 despite a certain degree of cell renewal 
capacity of cardiomyocytes in both mice 107 and humans.108 However, the heart regeneration 
extent is still under active discussion,109, 110 as the turnover and source of cardiomyocytes are 
not clarified, attributed to endogenous and exogenous progenitor cell niches,111-112 or even to 
the division of existing cardiomyocytes.113 Thus, research efforts are intensively continued 
towards the development of novel cardiac regeneration therapies. 
 
Small drug molecules and biologics 
 
Small drug molecules and biologics constitute promising deliverables for MI therapy. 
Particular advantages make these entities attractive, such as often inexpensive fabrication and 
storage. Advances in synthetic chemistry have led to large libraries of structurally diverse 
molecules that are screened for efficacy, identification of new molecular targets and elucidation 
of unknown signaling pathways involved in the pathology of MI. For example, stabilization of 
the calcium cycling process in cardiomyocytes is regarded a new therapeutic target, bringing 
up to light new drug molecules, such as derivatives of 1,4-benzothiazepine for stabilization of 
the type 2 ryanodine receptors,114 or omecamtiv mecarbil, a compound that enhances the 
sensitivity of cardiac myosin to calcium to improve cardiac function.115 Another example, 
pyrivinium pamoate, which is specifically cytotoxic for fibroblasts, has been investigated as a 
potential drug for anti-fibrotic therapy.116  
There is an increasing interest in the screening and development of small drug 
molecules for myocardial regeneration purposes.117 Enhancement of cardiomyocyte 
proliferation was previously achieved with the administration of fibroblast growth factors, 
neuregulin 1, periostin or prostaglandin E2.118-121 In contrast, direct reprogramming of cells 
into cardiomyocyte-like cells is another strategy to repair the injured myocardium. Sole or 
combinational therapy with small drug molecules has also shown successful in cell 
reprogramming. A list of small molecules used for cardiac reprogramming is listed by Xie et 
al.122 As an example, a combination of CHIR 99021 (glycogen synthase kinase 3β (GSK3B)), 
SB431542 (transforming growth factor (TGF)-? signaling inhibitor), parnate ((LSD1/KDM1 
inhibitor) and forskolin (adenylyl cyclase activator), in combination with the transcription 
factor Oct4, led to the direct reprogramming of mouse fibroblasts into induced 
cardiomyocytes.123 This is a trivial demonstration of the great potential of small drug molecules 
towards the achievement of cardiac regeneration, a sub-field of the therapy for CVD that is 
emerging fast. 
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MicroRNA therapy  
 
Among the different gene therapeutic approaches, microRNA (miRNA) is currently in 
the spotlight regarding the gene therapy for MI.124 They can be used, for example, in the 
inhibition of hypertrophy125, 126 or as cardioprotection of apoptotic effects of ?-blockers.127 
Cardiac reprogramming has been also achieved using miRNAs. The administration of different 
miRNAs (1, 133, 208 and 499) induced a low-efficiency reprogramming of murine fibroblasts 
into cardiomyocyte-like cells.128 A recent study showed that combination of transcription 
factors (Gata4, Hand1, Tbx5, and myocardin) and miRNAs-1 and -133 successfully induced the 
reprogramming of human fibroblasts into cardiomyocyte-like cells.129  
 
Cell therapy 
 
 Transplantation of stem or progenitor cells into the injured heart brings up hope that 
new cardiac tissue is regenerated with, therefore, improved cardiac function. Thus, scientists 
and healthcare professionals see great potential in cell therapy for MI patients. A high number 
of cell types has been investigated for cardiac regeneration purposes in vast preclinical and 
clinical trials.130 The included cell types are skeletal myoblasts, embryonic stem cells (SCs), 
bone marrow-derived mesenchymal SCs, adipose-derived mesenchymal SCs, embryonic SCs 
and cardiac SCs. Although the different cell types tested have shown potential benefits in vitro 
and in pre-clinical trials,131-138 only cardiac and cardiopoietic SCs demonstrated the most 
promising results regarding efficacy.139-143 For example, the C-CURE clinical trial investigated 
the transplantation of cardiopoietic mesenchymal SCs to MI patients, with demonstrations of 
improved safety and efficacy results, such as 7% increase in LV ejection fraction, improved 
exercise tolerance and positive effects on hemodynamics.143  
  
Tissue engineering 
 
A major problem in the clinical translation of cell therapy is the delivery and retention 
of cells in the cardiac tissue, as the majority of the transplanted cells do not preserve viability 
and are not able to provide a therapeutic effect. The administration strategy of cells can also 
constitute a problem, implying the suspension of cells in saline for systemic infusion, perfusion 
into the coronary vessels and direct injection into the injured myocardium, strategies that do 
not provide a proper environment for cell survival, or have the ability to localize and retain the 
cells at the target site.110, 144-147 Biomaterial scaffolds and carriers were brought up as a solution 
for cell delivery to the target site, engraftment of cells to the injured tissue, and maintenance 
of cell viability, by engineering them to provide a favorable environment for cell survival and 
proliferation. In addition, they may promote the production of beneficial paracrine factors, and 
have additional effects by exerting mechanical therapy and offering physical support. These 
systems are mainly formulated as cell-loaded in situ polymerizable injectable hydrogels or pre-
formed cell-seeded scaffolds, attachable to the epicardium.130, 148, 149 Moreover, cardiac 
scaffolds and hydrogels can be applied as cell-free substrates for promoting mechanical 
reinforcement, tissue bulking in the scar zone, and serve as protective and drug delivery 
systems. In the field of cardiac tissue engineering, several natural or synthetic materials have 
been applied to form the backbone of the engineered substrate. Examples of cell-loaded and 
cell-free biomaterials for cardiac tissue engineering applications comprise hydrogels made of 
fibrin,150-152 polyethyleneglycol,153, 154 alginate 155 or chitosan.156, 157 Pre-formed scaffolds may be 
composed of, for instance, collagen,158, 159 chitosan,160 and hemoglobin/gelatin/fibrinogen.161 
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Particulate systems 
 
Over time, the research focus of CVD treatment has been expanded to different areas, 
some of them already reviewed above. The use of particulate systems for the treatment and 
diagnostics/imaging of MI has arisen in recent years to overcome important obstacles of 
traditional and developing therapies: to target the injured myocardium, to overcome the 
problems of extremely invasive administration routes, to provide protection for short half-life 
biologicals, to improve the physical properties of drug cargos, such as the solubility and 
stability, and to promote controlled delivery of one or more therapeutic drugs.10, 162 Although 
some literature references still describe the use of (micro) particulate systems for local 
administration into the myocardium, micro- and nanoparticles have been developed to avoid 
this invasive need, an important factor to take into account when considering clinical 
translation.14, 163  
The next section will be devoted to reviewing previous reports on micro- and 
nanoparticulate systems developed for the therapy and diagnostics/imaging of MI. The main 
developing therapeutic strategies for MI are presented in Figure 4.  
  
 
 
 
Figure 4. Summary of the different therapies used for the treatment of MI under 
investigation. The figure was constructed partly using Servier Medical Art. 
 
 
2.2. Overview of micro- and nanoparticulate-based medicines for 
cardiovascular diseases 
Although there are several therapeutic options for MI patients, there is no cure for this 
burden. As mentioned above, the prevalence of mortality and morbidity cases is plentiful, and 
the limited efficacy and harmful side effects of therapeutics and invasive procedures greatly 
affect the patients’ quality of life. Along with other investigated therapeutic strategies, the 
development and application of micro- and nanomedicines for CVD is now increasing.9 
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Regarded as versatile tools, particulate carriers possess tailoring properties by changing the 
material’s shape, chemically modifying and attaching the particle surfaces with targeting, 
imaging, and therapeutic moieties, or simply loading them with therapeutic and/or imaging 
entities (Figure 5).164 For example, liposomes have the ability to entrap high amounts of 
payloads,165 and polymeric and metal oxides may be functionalized with a variety of ligands for 
different purposes.166 Particles may also be functionalized to improve the biodistribution,167-169 
act as therapeutic entities themselves, 170 or serve as DDS for poorly-water soluble drugs, thus 
improving their dissolution rate due to the particle’s high surface-to-volume ratio.171, 172 
Researchers are now gathering all these features to the availability of comprehensive 
information about the cardiac pathological processes at the cellular and molecular levels. As a 
result, micro- and nanomedicine are evolving as a multidisciplinary field to circumvent the 
limitations of conventional therapy, which is truly important in the diagnostics and treatment 
of CVD.173 Examples of particulate-based carriers for therapeutic and imaging purposes are 
summarized in Table 2.  
 
 
 
Figure 5. Parameters for micro- and nanoformulation design. Properties of the carrier can be 
tailored from the perspective of size, material composition, shape, surface chemistry, targeting 
ligand conjugation, and payload, in order to overcome the sequential physiological barriers for 
precise drug delivery. Copyright © 2017 the American Physiological Society. Adapted and 
reprinted with permission from ref.164. 
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Table 2. Micro- and nanoparticulate systems developed for the therapy and imaging of MI. 
Abbreviations: MPs, microparticles; NPs, nanoparticles; PEG, polyethylene glycol; PLGA, poly(lactic-
co-glycolic acid); USPIO, ultrasmall superparamagnetic iron oxide. 
Micro- and nanosystems Purpose 
Administratio
n route 
Targeting 
strategy 
 
Refs. 
PLGA NPs Therapeutics 
delivery 
 
Imaging 
 
Gene delivery 
 
 
 
 
 
 
Intramyocardial 
 
_ 174-176 
Chitosan?alginate NPs 
Chitosan hydrogel NPs 
 
_ 
177, 178 
Gelatin MPs _ 179-181 
Acetalated dextran MPs _ 182, 183 
siRNA Polyketal NPs 
 
Gene delivery 
 
 
_ 184, 185 
siRNA-dendrimers 
Poly(glycoamidoamine) 
oligodeoxynucleotide polyplexes 
 
Pericardial sac 
 
_ 
186 
Peptide-polymer amphiphile 
nanoparticles 
Therapeutic 
delivery 
Intramyocardial 
Intravenous 
Passive 187 
Liposomes 
Therapeutics 
delivery 
 
Intracoronary 
 
_ 
188 
PEGylated polystyrene NPs 
PEGylated micelles 
Potential 
application in MI 
therapy 
 
 
 
Intravenous 
 
 
 
 
Passive 
189 
190 
PEGylated liposomes 
Micelles, Liposomes 
Therapeutics 
delivery 
Imaging 
 
Passive 
Active 
 
163, 191-195 
Liposomes 
Immunoliposomes 
Platelet-like proteoliposomes 
Therapeutics  
delivery 
Imaging 
Gene delivery Passive 
Active 
99, 196-203 
Solid lipid nanoparticles Therapy and 
therapeutics 
delivery 
204 
Peptide-PEG-polylactic acid 205 
Gold NPs 
Therapeutics  
delivery 
 
Oral gavage 
_ 206 
Polyelectrolyte-coated  
gold nanorods 
Antifibrotic 
therapy 
_ _ 
170 
Silica nanoparticles 
Therapeutics  
delivery 
Intravenous 
infusion 
Passive 207 
Iron nanoparticles 
Imaging  
Therapy 
Intravenous Active 208 
USPIO NPs 
 
Bolus 
 
Active 
209, 210 
SPIO nanoparticles Imaging 
Intravenous 
Active 211, 212 
Perfluorocarbon nanoemulsions Therapy 
 
Passive 
213 
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2.2.1. Administration routes 
 
The administration routes often employed for micro- and nanomedicines for the 
therapy of MI are local intramyocardial, pericardial, intracoronary and i.v. administration. 
Oral administration is a rare route of administration of particulate carriers for MI therapy but 
has also been attempted.206 Some examples of locally administered micro-and nanomedicines 
are presented next and included in Table 2. Chang et al. demonstrated that a single 
intramyocardial administration of insulin growth factor (GF)-loaded poly lactic-co-glycolic 
acid (PLGA) nanoparticles prolonged Akt phosphorylation and provided cardioprotection for 
up to 24 h, which was sufficient to improve cardiac systolic function, reduce infarct size, and 
prevent ventricular remodeling 21 days after MI in mice.174 Similarly, Binsalamah et al. have 
injected placental GF-loaded chitosan-alginate nanoparticles intramyocardially in MI-induced 
rats. Besides a sustained release of the cargo over several days, the outcomes observed were 
significantly increased LV function, vascular density and serum levels of the anti-inflammatory 
cytokine interleukin-10, together with decreased scar area formation and reduced amounts of 
pro-inflammatory cytokines.177 Other reports have also demonstrated the use of particulate 
systems made of different materials for intramyocardial injection in injured hearts.175, 176, 179-182, 
184, 185  
Tranter et al. administered low toxic glycopolymer-based polyplexes carrying 
oligodeoxynucleotide decoys in the pericardial sac, for the transfection of ventricular 
cardiomyocytes in vivo.186 Intracoronary administration was based on the direct infusion of 
therapeutics into the coronary arteries. Verma et al. administered adenosine triphosphate 
(ATP)-loaded liposomes directly to the coronary artery in a rabbit MI model as a source of 
exogenous ATP for the protection of ischemically damaged cells.188 Oral gavage was attempted 
by Vinodhini et al. for cardioprotective therapy using gold nanoparticles loaded with 
antioxidant proanthocyanidin.206  
To tackle the need of surgery for the administration of cell-based therapy,12 cardiac 
scaffolds,13 or microparticulate medicines into the injured heart, the tendency is to develop 
nanoparticles that are possible to be administered by minimally invasive routes such as the i.v. 
route. In the 1970s, a study using plain radiolabeled liposomes of different surface charges 
showed that liposomes have the ability to accumulate in the infarcted zones and could serve as 
potential vehicles for delivery of therapeutics for the treatment of MI.214 From this point on, an 
increasing research towards the development of nanomedicines for i.v. injection took off.10, 162, 
189, 191, 215, 216 More examples of developed particulate systems are given in the next section. 
 
 
2.2.2. Targeting approaches 
 
Targeting is considered when the main purpose is to develop a drug delivery 
nanocarrier to be administered by less invasive administration routes, such as oral, nasal or i.v 
administration. Focusing on i.v. administration, either active or passive targeting are the 
mainstream approaches for the delivery of cargos to prevent, alleviate and treat several 
diseases, such as cancer and MI. While passive targeting is based on the enhanced retention of 
the nanocarriers in the diseased tissue due to the increased microvascular permeability, active 
targeting relies on the interaction between a particular ligand attached on the surface of the 
carrier and a distinctive disease marker (over)expressed on the cell membrane. Both 
approaches theoretically lead to an increased amount of delivered therapeutics into the injured 
tissue area compared to the healthy tissue. 217  
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2.2.2.1. Passive targeting 
 
Similarly to solid tumors,218 it has been shown that the vascular permeability is 
transiently increased upon an ischemic event in the myocardium.219 This fact allows the 
exploitation of passive targeting of nanomedicines to the injured heart, although it is known 
that in many cases, a leaky vasculature is not enough to allow optimal delivery of therapeutic 
compounds.220 Taking advantage of this, Lundy et al. investigated the ideal particle size for 
rapid passive targeting of the myocardium by systemic administration of polyethylene glycol 
(PEG)-polystyrene nanoparticles soon after ischemia−reperfusion injury. They observed that 
a wide range of particle sizes is able to accumulate in the injured LV compared to sham-
operated models, ranging from core diameters of 20–200 nm, while 500 nm particles (and 
bigger) showed also accumulation in the injured LV, and also a much greater off-target 
retention in the spleen.189 Liposomes have been used widely for passively targeted drug 
delivery, as their accumulation in regions of experimental MI has been demonstrated.188, 190, 191, 
221 Nguyen et al. developed enzyme-responsive nanoparticles for targeted accumulation in the 
infarcted heart upon MI. These nanoparticles, made for passive targeting due to their small 
size and relying on the leaky vasculature of the injured myocardium, were made of peptide-
polymer amphiphiles and contained specific peptide sequences for the recognition of matrix 
metalloproteinases 2 and 9, which are upregulated in MI. They demonstrated, both by 
intramyocardial and i.v. injections, a change in nanoparticle conformation upon reacting to 
the presence of matrix metalloproteinase 9 in the infarcted myocardium, to an aggregate-like 
scaffold, and a retention for up to one month. Although not showing loading of therapeutic 
cargos or beneficial functional outcomes, this study opens up new doors for potential 
prolonged therapeutics delivery.187 
Other materials have been used as nanoparticulate vehicles for passive delivery. 
Examples include silica,207 and perfluorocarbons.213 The latter ones were used as oxygen 
carriers to the ischemic myocardium, as perfluorcarbons have high ability to carry great 
volumes of respiratory gases physiologically. They accumulated in the ischemic areas of the 
heart by passive targeting, due to their small size, and demonstrated infarct size reduction in a 
murine MI model.213 These and other examples of nanosystems used for passive targeting to 
the ischemic heart are summarized in Table 2.  
  
  
2.2.2.2. Active targeting 
 
The development of targeted DDS is an urgent need to maximize the overall efficacy of 
the delivered drugs for cardioprotection. Poor targeting to the infarcted heart is an issue, 
because this may lead to both failure in treatment and also induce unwanted side-effects in 
other organs.222 One example was the encapsulation of cyclosporine in PEG-coated (or 
PEGylated) liposomes and administration to patients with MI in a clinical trial, revealing a 
distribution of cyclosporine mainly in other organs rather than in the heart. The failure of this 
trial was due to the transitory leaky vasculature effect upon MI, contrarily to what happens in 
tumors, which showed a sustained enhanced permeability and retention effect. Thus, relying 
on a leaky vasculature is insufficient for meaningful therapeutic outcomes.223 Furthermore, a 
specific cardiomyocyte marker suitable for targeting has not been yet found.224 Therefore, in 
vivo phage display is typically used instead, for the discovery of potential peptide targeting 
ligands,203 or peptides targeting the low extracellular pH of the infarcted myocardium.225, 226 
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In this case, different targeting moieties or strategies are attempted to home the drug(s) 
to the injured LV. Peptides and antibodies are some of the targeting moieties utilized to 
functionalize the surface of nanocarriers for targeted drug delivery to the injured myocardium. 
For the first time, InCl3-radiolabeled liposomes functionalized with antibodies to cardiac 
myosin were used to visualize the infarcted heart in a dog experimental MI model. After 
transient blockade of the left coronary artery, immunoliposomes were administered i.v. and 
accumulated preferentially in the infarcted zone.196 Dvir et al. targeted the MI heart by 
functionalizing liposomes with antibodies against angiotensin II type 1 receptor, overexpressed 
in the infarcted heart, showing successful in vivo targeting, however without incorporation of 
drug molecules into the functionalized liposomes, and not showing relevant biological effect.99 
Similar approaches have also been presented using antibodies as targeting moieties.197-200, 227 
Dasa et al. used the in vivo phage display tool for identification of peptides that would be 
specific for the different cardiac cells present in the heart, including among others, 
cardiomyocytes and cardiac progenitor c-Kit+ cells found in the border zone of the infarct area. 
After further conjugation of the discovered peptides onto liposomes’ surface, pharmacokinetic 
studies reveal significantly higher liposome accumulation in the heart and more efficient drug 
delivery.201 Cheng et al. exploited the fact that splenic monocytes are highly recruited to the 
heart after an MI event, and are known to interact with platelets during circulation.202 They 
developed platelet-like proteoliposomes, which biomimic platelet interactions with circulating 
monocytes. Their results showed affinity of the nanocarriers for monocytes, but not for 
endothelial cells in vitro, mimicking normal platelet activity. In vivo, the platelet-like 
proteoliposomes accumulated at the injury site 72 h postinfarction and provided targeted drug 
delivery to the heart in an enhanced vascular permeability-independent manner, 
demonstrated anti-inflammatory effects and overall improvement in cardiac function. A 
similar approach to target cardiac macrophages towards a reparative state was also used by 
Harel-Adar et al.,201 by creating phosphatidylserine-presenting liposomes that mimic anti-
inflammatory effects of apoptotic cells. This induced the expression of anti-inflammatory 
cytokines, resolved inflammation, and promoted angiogenesis, and prevented negative 
ventricular remodeling in vivo in a MI rat model. Cheng et al.208 utilized iron oxide 
nanoparticles, functionalized with two types of antibodies (one type against CD45 found in 
bone marrow-derived SCs and the other against CD34 expressed in injured cardiomyocytes) 
for delivery of SCs to the injured myocardium and possibility of non-invasive imaging. 
Targeting could be further enhanced by magnetic attraction and functional improvements in 
the LV ejection fraction were observed after 4 weeks, however, the imaging could be 
compromised by the degradation and absorption of the iron nanoparticles. In addition, the 
therapeutic efficacy was limited by possible insufficient SCs in the circulation for capture by 
the nanoparticles, and the time of administration immediately after acute MI requires further 
investigation of later administration time points.208 More recently, Huang et al. targeted highly 
expressed fibrin in the injured area of the myocardium.205 For this, they attached the clot-
binding peptide cysteine–arginine–glutamic acid–lysine–alanine to PEG-polylactic acid 
nanoparticles to mediate their interaction with fibrin in the infarcted zone. They demonstrated 
the accumulation in the infarcted zone and delivery of thymosin beta 4 in vivo upon i.v. 
administration, with a reduction in infarct size and scar formation (Figure 6). 
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Figure 6. Fibrin-targeted CNP–Tβ4 accumulation in the infarcted heart (A) and reduction of 
the infarct size and scar formation with CNP–Tβ4 after MI in mice (B). Abbreviations: CNP–
Tβ4, cysteine–arginine–glutamic acid–lysine–alanine and thymosin beta 4 conjugated to 
nanoparticles; PBS, phosphate-buffered saline; NP–Tβ4, thymosin beta 4 conjugated to 
nanoparticles; DAPI, 4′,6-diamidino-2-phenylindole; NP, nanoparticle. Copyright © 2017 
Dove Medical Press Limited. Adapted and reprinted with permission from ref. 205. 
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2.2.2.3. Imaging of MI with nanoparticulate systems 
 
Imaging of the infarcted area is another interest of the medical and scientific 
community, as conventional methods do not allow an optimal and detailed visualization of the 
different pathological states of the injured myocardium in patients at risk (such as myocardial 
edema and hemorrhage). Iron oxide nanoparticles have been widely studied as contrast agents 
for magnetic resonance imaging, and are the most common nanoparticulate-based approach 
studied for imaging of MI.208, 228 In this context, and making use of both passive and active 
targeting approaches, ultrasmall superparamagnetic iron oxide nanoparticles (SPIOs) were 
developed and used in a phase III clinical trial with MI patients for cardiovascular magnetic 
resonance imaging. The principle of this study was based on the targeting of the infiltrating 
macrophages of the (peri-) infarct zone.209 In addition, another study from the same group 
demonstrated the dual advantage of ultrasmall SPIO for theranostics.208 Other studies 
included antibody and heat shock protein 70-functionalized iron oxide nanoparticles for 
magnetic resonance imaging of infarcted hearts,211, 212 liposomes and micelles.193, 194 Shevtsov 
et al. explored the use of heat shock protein 70-functionalized SPIO nanoparticles as contrast 
agents for MI imaging, since it has been demonstrated that the receptor for this ligand is 
expressed in cardiomyocytes.229 They showed that the functionalized SPIO nanoparticles 
provided high contrast potential for diagnosis of injured areas of the rat MI heart (Figure 7), 
due to an elevated expression of the heat shock protein-70 receptor in the stressed MI tissue. 
212 Other strategies to image the MI heart include radiolabeling of nanoparticles,178 liposomes 
and micelles containing paramagnetic and fluorescent lipids,163, 192 and gadolinium-labeled 
liposomes.193, 194 These systems are summarized in Table 2.  
 
 
 
Figure 7. Imaging of the myocardial infarct. Magnetic resonance images were taken for 
control untreated animals, animals treated with SPIO nanoparticles, and heat-shock protein-
70 (Hsp70)-SPIO nanoparticles. Copyright © 2015 Elsevier B. V. Adapted and reprinted with 
permission from ref.212. 
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2.3. Drug delivery systems 
 
2.3.1. Porous silicon   
 
Porous silicon (PSi) was first reported by the Uhlirs in 1956 as an unwanted side product 
of electrolytic shaping of silicon.230 This phenomenon was later investigated by Turner, who 
electrochemically dissolved silicon wafers in aqueous or ethanolic hydrofluoric acid solutions, 
and established the detachment of a dark layer from the silicon wafer after increasing the 
current density above a critical point − the electropolishing region.231 However, only in 1971, 
Watanabe et al.232 recognized the porous nature of this layer and an increasing interest for this 
material took-off. After Canham demonstrated the first hints of photoluminescence, bioactive 
properties, and the ability to convey bioinert and bioactive nature of PSi233, 234, the application 
of PSi in biomedicine became extremely popular.235-237 
 
 
2.3.1.1. Fabrication and surface stabilization of PSi materials 
 
PSi is fabricated by a top-down approach, which makes it easy for scaling-up. The 
distinct properties of this material make it attractive and advantageous for biomedical 
applications. Among them, biocompatibility, biodegradability, high surface-to-volume ratio 
and surface area, porosity, pore size and volume, tunable surface chemistry, stability, shape 
and particle size make PSi interesting for use in therapeutic drug delivery and biosensing.17, 23, 
29, 238-240  
The most common fabrication method of PSi is electrochemical anodization in aqueous 
or ethanolic electrolytes of hydrofluoric acid.18, 23, 241, 242 The silicon wafer is in contact with a 
conductive metal anode, and usually, platinum is used as a cathode. A porous structure layer 
is formed upon application of an etching current at the surface of the silicon wafer. The 
porosity, porous layer thickness, shape and size of the pores are tunable properties, determined 
by several factors and parameters during the electrochemical anodization process.17, 241, 243  
The freshly etched PSi is hydrogen terminated (Si-Hx), and thus, very unstable and 
prone to oxidation, going from hydrophobic to hydrophilic oxidized surface over time, with 
loss of optical and structural properties of the material.241, 244, 245 To avoid this phenomenon, 
there are strategies to stabilize the surface of PSi. Examples include controlled oxidation, 
thermal hydrocarbonization (THC), hydrosilylation and thermal carbonization (TC).239 
Thermal oxidation (TO) of PSi (TOPSi) provides a hydrophilic Si–O surface to the PSi material, 
by thermal, chemical, photo and anodic methods.242, 244 TO facilitates wettability and 
degradation in physiological fluids. In addition, by imparting a relatively fast degradation in 
aqueous media, the stability of the material against dissolution is affected, and may not be 
always the best choice when longer-term dissolution profiles are required. In this case, surface 
functionalization with carbon is commonly used. Hydrosilylation gives a Si–C surface to the 
PSi material through a thermal, photo or Lewis-acid catalyzed reaction of alkene or alkyne with 
Si–H bond, and yielding better hydrolytic stability.18, 242 TC and THC are based on the thermal 
addition of carbons from acetylene molecules onto the surface of PSi; the temperature differs 
from 450−680° C for THC and above 700° C for TC. TC and THC yield hydrophilic TCPSi and 
hydrophobic THCPSi.246 The further functionalization of THCPSi with –COOH groups is 
possible by thermal treatment with undecylenic acid,247 making it easier for the covalent 
attachment of ligands for diverse nanocarrier biofunctionalization. Due to the numerous 
properties and advantages of PSi material, stabilized PSi are turned into micro- and 
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nanoparticles, generally using lithography, imprinting method, ball milling or ultrasonic 
fracturing, followed by sieving and/or centrifugation or filtering, to separate the different size 
fractions of micro- and nanoparticles.248-253  
 
 
2.3.1.2. Progress in porous silicon-based particulate systems for biomedical 
applications  
  
PSi micro- and nanomaterials have been extensively studied and employed for 
biomedical applications due to the above above mentioned attractive properties. The different 
forms of PSi available, such as layers, membranes, micro- and nanoparticles, make this 
material versatile for different purposes.239  
For drug delivery, micro- and nanoparticles are the most important and widely used 
forms of PSi. 17, 242 Enhancement of the dissolution rate of poorly water-soluble drugs is one 
advantage of using nanocarriers due to the high surface-to-volume ratio and surface area. 236 
In addition, by being highly porous, PSi confines drug molecules in an amorphous-like state or 
nanocrystalline form, which impacts the dissolution rate of a drug compared to its crystalline 
form. 254 Meeting these criteria, PSi materials seem to be extremely helpful in the enhancement 
of the dissolution rate of various extremely poorly water-soluble drugs. 255, 256  
PSi micro- and nanoparticles have been proved to be suitable for different applications, 
such as the therapeutics and imaging of cancer,26, 256-258 diabetes,20, 25, 259, 260 immunotherapy,21, 
24, 261 and, recently, also as a nanoreactor,262 to name a few. Investigation of PSi materials for 
different administration routes concludes that the hydrophobic THCPSi is the most suitable 
for oral drug delivery.19 Surface modification was needed to improve retention time in the 
gastrointestinal tract, although not in an ideal fashion when the particles reach the small 
intestine.263 Thus, as an application for diabetes therapy, to impart a prolonged gastric transit, 
PSi particles have been surface-modified with mucoadhesive chitosan and/or coated with 
enteric polymers, in order to resist the harsh conditions of the stomach and deliver peptide or 
protein therapeutics in the intestine.20, 25, 259, 260, 264 Mucoadhesivity of PSi materials is also 
achieved for gastrointestinal related cancer therapy, with poly(methyl vinyl ether-co-maleic 
acid), to maximize the benefits of dual drug delivery of anticancer payloads.27 In many cases, 
the parenteral application of PSi for anticancer drug delivery requires other types of 
functionalization, for example, to prevent payload leakage from the PSi pores, shielding from 
the reticuloendothelial system, or targeting the tumor site. Pore capping and nanoparticle 
shielding can be achieved by encapsulating or coating drug loaded-PSi carriers with bioinert 
lipids, DNA, polymers or cyclodextrins.257, 265-267 Targeting of tumors may be accomplished by 
functionalizing the PSi carriers with specific ligands to target (over)expressed receptors or 
proteins at the cell surfaces.22, 26, 268 PSi nanocarriers have been also explored for the 
applications in immunotherapy.240 While screening of the different PSi nanoparticles was 
useful to determine which surface chemistries induced the higher immunostimulation,24 it also 
allowed further investigation of functionalized PSi materials for targeted261 cancer 
immunotherapy,21 and insights in the development of particulate-based vaccines.269 Finally, as 
next generation therapeutics, PSi nanoparticles have also been cell membrane-encapsulated 
with the aim to create bioinspired artificial organelles, in order to mimic subcellular organelle 
functions for supplementing pathological cellular dysfunctions.262 In Table 3 are provided 
examples of the applications of particulate PSi materials in the biomedical field.  
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Table 3. PSi micro- and nanoparticles for diverse biomedical applications. 
Application PSi In vitro cell 
model 
In vivo 
model 
Main conclusions Refs. 
Oral drug 
delivery  
TCPSi 
TOPSi 
In vitro 
dissolution 
_ Hydrophilic drugs: 
sustained release 
Hydrophobic drugs: 
improved dissolution 
255 
Healthy rat 254 
THCPSi 
Caco-2 
RAW 264.7 
Healthy rat 
In vivo stability 
Biocompatibility 
Ideal for oral delivery 
In vivo imaging of the 
transit of particles in the GI 
tract 
19 
AGS 
Enhanced GI transit in 
stomach, not in intestine 
263 
Cancer  
 
APTES− 
TCPSi 
U87 MG 
EA.hy926 
_ 
Dual drug delivery 
Improved dissolution rate  
Enhanced antiproliferation 
effect 
256 
LPSiNPs HeLa 
MDA-MB-
435 tumor 
bearing mice 
Biodegradability 
Biocompatibility 
Tumor imaging 
29 
UnTHCPSi 
Caco-2  
HT-29 
_ 
pH-controlled dual drug 
delivery  
Mucoadhesion 
Antiproliferation effect 
27 
PC3MM2 
PC3-MM2 
tumor 
bearing mice 
Tumor accumulation and 
targeted drug delivery  
In vivo tumor imaging 
26 
MCF-7 
MDA-MB-231 
_ 
Colloidal stability 
Sustained drug release 
Antiproliferation effect 
266 
MCF-7 _ 
pH-dependent release 
Targeted antiproliferation 
effect 
22 
MDA-MB-231 _ 
Superior intracellular multi-
drug/theranostic delivery 
Endosomal escape 
257 
THCPSi 
HT-29 
HepG2 
RAW 264.7 
_ 
Cytocompatibility 
Controlled release  
Colloidal stability 
265 
RAW 264.7 
PC3MM2 
_ 
Production by microfluidics 
– homogeneous 
nanocarriers 
pH triggered drug release 
pH-dependent cytotoxicity 
Minimal macrophage 
interactions 
267 
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Diabetes  UnTHCPSi 
Caco-2  
HT-29  
AGS 
 Raji B 
_ 
Improved insulin/GLP-1 
permeation across intestinal 
cell monolayers 
Protection of peptide cargo 
from acidic GI conditions.  
Dual drug delivery 
 20, 25, 
259 
_ 
Type-2 
diabetes rat 
model 
Notable adhesion to rat 
intestinal epithelia 
Decrease in blood glucose 
levels 
Increase in pancreatic 
insulin content 
264 
(Cancer) 
Immuno-
therapy 
APM 
TOPSi 
UnP 
UnTHCPSi 
TCPSi 
THCPSi 
APTES-
TCPSi 
PBMC 
PBL 
_ 
Surface chemistry-
dependent 
immunomodulation 
24 
APTES 
oxidized PSi 
BMDC 
BALB/c 
C57BL/6 
C57BL/6-
Tg(TcraTcrb) 
PSi phagocytosis 
BMDC activation and 
migration to lymph nodes 
Antigen-mediated T-cell 
activation 
269 
TOPSi 
KG1 
BDCM 
_ 
Cytocompatibility 
Co-stimulatory signal 
induction 
Multistage nanovaccines 
with adjuvant properties 
21 
Biomimetic 
organels 
UnTHCPSi MDA-MB-231 _ 
High catalytic activity 
Cytocompatibility 
Govern the transport of 
molecules 
Intracellular stability 
Protection of payload 
leakage 
262 
Abreviations: BDCM, B-cells with dendritic cells morphology; BMDC, bone marrow dentritic 
cells; GI, gastrointestinal; GLP-1, glucagon-like peptide-1; LPSiNPs, Luminescent PSi nanoparticles; 
PBMCs, peripheral blood mononuclear cells; PBL, peripheral blood lymphocytes; TCPSi, thermally 
carbonized PSi; APTES−TCPSi, (3-aminopropyl)triethoxysilane functionalized TCPSi; APM, 
poly(methyl vinyl ether-alt-maleic acid) conjugated APTES-TCPSi; THCPSi, thermally hydrocarbonized 
PSi; UnTHCPSi, undecylenic acid functionalized THCPSi; UnP, polyethyleneimine conjugated 
UnTHCPSi, TOPSi, thermally oxidized PSi. 
 
 
2.3.2. Acetalated dextran  
 
The biocompatible and FDA approved dextran is a polysaccharide used for decades, for 
example, as a plasma expander.270 Reported first by Bachelder et al.,271 the properties of this 
polysaccharide were tuned to modulate compound solubility in a pH-dependent manner, by 
modifying the hydroxyl groups with acetal moieties through reaction with 2-methoxypropene 
under acid catalysis. In this reaction, kinetically favorable acyclic acetals are initially formed, 
followed by the formation of more thermodynamically stable cyclic acetals. The resulting 
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polymer, acetalated dextran (AcDX), is insoluble in water and freely soluble in common 
organic solvents, such as dichloromethane, ethyl acetate or acetone. The acetal formation 
depends on the reaction time and leads to varying degrees of degradation rate, based on the 
ratio of cyclic to acyclic acetals.271 This enables easy preparation of acid-sensitive particles, an 
attractive property for biomedical purposes, as acid-sensitive nanocarriers are of great 
interest for application in pathologies where mildly acidic conditions govern, such as in 
tumors and in inflammation, or even in lysosomal compartments of the targeted intracellular 
drug delivery.272, 273  
 Cohen et al. reported a variation of AcDX, by further functionalizing it with the 
polyamine spermine, to overcome the difficulties of encapsulating negatively charged cargos 
into the neutral AcDX. Spermine-AcDX (AcDXSp) is produced by a reductive amination 
chemistry, where spermine is covalently conjugated to aldehyde functional groups previously 
generated by oxidation of dextran using sodium periodate. Biocompatibility is reported, while 
the mildly acidic pH-dependent degradation is maintained.274  
 Micro- and nanoparticles made of polymeric materials are usually prepared by 
standard emulsification. An emulsion is formed by mixing an organic phase consisting of the 
polymer and hydrophobic cargo(s) to be entrapped, with a stabilizer or surfactant in the 
aqueous phase. When mixing together, the polymer starts to precipitate at the interface 
between the organic and aqueous phases. This mixing is done by applying external energy, 
breaking the organic phase into droplets and creating an oil-in-water (o/w) emulsion. After 
evaporation of the organic solvent, these droplets lead to the formation of micro- or 
nanoparticles, which contain the hydrophobic cargos entrapped. Different factors contribute 
to the particle size and encapsulation efficiency of loaded cargos, such as the type and 
concentration of surfactant, sonication, evaporation and centrifugation parameters.275, 276 The 
most common preparation methods of AcDX micro- and nanoparticles are the o/w single 
emulsion and water-in-oil-in-water (w/o/w) double emulsion techniques, followed by solvent 
evaporation. The choice of a single or double emulsion depends on the cargos to be loaded. 
While the entrapment of hydrophobic cargos can be achieved by a single emulsion, the 
entrapment of hydrophilic drugs or biologics requires a double emulsion, confining the 
hydrophilic cargos in the aqueous core of the nanodroplets.182, 183, 271, 277-280 
 
 
2.3.2.1. Progress in acetalated dextran-based particulate systems for biomedical 
applications  
 
The biocompatibility of AcDX is related to its degradation products, which are dextran, 
methanol (harmless in small quantities)281 and acetone (harmless metabolic intermediate). 
Toxicity tests of AcDX particles in different cell lines did also not show significant toxicity 
values.271 Combined with the acid-sensitive degradation profile, it is justifiable that quite much 
research for application in biomedicine has been conducted with this polymer. 
One of the undeniable applications of AcDX is in immunotherapy. Bachelder et al. 
assessed the feasibility of using AcDX for vaccine applications, by incubating the antigen 
ovalbumin. They observed a significantly enhanced antigen epitope presentation, suggesting 
the potential of this material in cancer immunotherapy.271 Other studies followed, including 
AcDX and AcDXSp encapsulation and attachment of different antigens for 
immunostimulation, cancer immunotherapy,21, 277, 279, 282, 283 and immunosuppression therapy, 
the latter one with the aim to reduce immunosuppressant side effects. 280 The modification of 
AcDX with spermine also brought up new opportunities for gene delivery. Cohen et al. 
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demonstrated that by functionalizing AcDX with spermine and making it cationic, it was 
possible to efficiently encapsulate and deliver siRNA.274 Taking advantage of the mildly acidic 
degradation of AcDX and AcDXSp, several studies demonstrated the polymer’s feasibility for 
cancer therapy,258 either the combination of anticancer drugs with different physicochemical 
properties, or different therapeutic modalities.284, 285 The potential use of AcDX for deep lung 
drug delivery was also explored, taking into consideration different degrees of acetalation to 
modulate the polymer degradation and the delivery of therapeutics at different pH 
conditions.286, 287 
Finally, AcDX has also been employed for the delivery of biologics for MI therapy. 
Suarez et al. studied the biocompatibility of AcDX to the heart and demonstrated an efficient 
entrapment of the model proteins myoglobin and basic fibroblast growth factor, and a 
controllable release of the cargos in some cases for more than 30 days, depending on the 
acetalation degree of the polymer.183 In another study, it was also evaluated the effect of 
hepatocyte growth factor-loaded AcDX microparticles on the efficacy in angiogenesis, 
cardiomyocyte apoptosis, and infarct size, in an MI animal model.182 Despite the therapeutic 
advantages demonstrated and sustained release of biologics, these microparticulate systems 
needed to be delivered intramyocardially, a considerable drawback for clinical translation and 
patient compliance.  
 
 
2.3.3. PEGylation for enhanced stability, biodistribution and targeting 
properties of nanosystems 
 
One of the greatest obstacles of systemically administered nano DDS is when they face 
the mononuclear phagocyte system in the blood stream. The body recognizes and clears foreign 
entities by using neutrophils, monocytes, and macrophages in the blood, liver, spleen, and 
lymph nodes, making systemic nano drug delivery difficult, by shortening the blood circulating 
time and tissue/cell distribution, and this makes their translation into the clinics difficult.288 
The most common approach to overcome this issue is to strategically coat the 
nanocarrier surface with an inert polymer, resistant to interactions with the constituents of 
blood and giving the nanocarrier “stealth” properties. 289 PEG has long been used as a stealth 
polymer, considered safe and approved by FDA. PEG has been reported for the first time for 
drug delivery purposes in the 1970s, after increasing the circulation time and decreasing the 
immunogenicity of proteins. 290 These positive observations escalated towards the 
investigation of PEG coatings of nanoparticles for systemic delivery. PEGylation is 
demonstrated to efficiently shield nanoparticles from aggregation, opsonization, phagocytosis, 
and increases the circulation time, providing a higher probability for the circulating 
nanosystems to find and distribute to the target tissues. After the example of FDA approved 
nanomedicine Doxil® “Stealth” liposomes, PEGylation became mainstream in nanoparticle 
formulation. The mechanism by which PEG shields nanoparticles from opsonization and 
makes them stable is related to the hydrophilic nature. 168 Nanoparticles coated with PEG 
generate a hydrated layer with a large excluded volume that sterically impedes nanoparticles 
from interacting with neighboring objects. 291 Additionally, because the PEG chains are highly 
flexible, the interpenetration of foreign matter into the PEG corona is not thermodynamically 
favorable. 292  
The use of PEGylation has been extended to nanomedicines for the treatment of MI. 
Studies described the use of different particulate systems coated with PEG to prolong the 
circulation time, maximize the effect of passive targeting, and improve the pharmacokinetics 
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of loaded cargos. 189-191, 195 As an example, Zhang et al. compared the effect of PEGylation of 
nanostructured lipid carriers bearing a short-lived payload in the plasma concentration and 
efficacy in an MI model. 195 They observed a 3-fold increase in the plasma concentration of the 
payload in PEGylated nanocarriers compared to non-PEGylated ones, as well as a higher heart 
drug concentration in the MI model, which in turn resulted in a significantly decreased infarct 
size. In other reports, PEGylation was combined with targeting moieties for prolonged 
circulation and maximized active targeting of MI. 99, 204 Dong et al. linked the targeting peptide 
arginyl-glycyl-aspartic acid (RGD) to PEGylated solid lipid nanoparticles for the targeting of 
???3 integrins, which was highly expressed in cardiac endothelial cells during angiogenesis for 
dual passive and active targeted drug delivery of an antioxidant and a reactive oxygen species 
scavenger. The passive targeting was owed to the small size of the solid lipid PEGylated 
nanocarriers, while the active targeting was reached with the RGD ligand at the carrier surface. 
The pharmacokinetics of the payloads were improved and the infarct size reduced. 204 In this 
thesis, PEG was also used as a tool to stabilize the developed nanosystems both in vitro and in 
vivo. 
  
 
2.3.4. Functionalization and radiolabeling of nanoparticles for theranostics 
 
The fast advancement of nanotechnology for biomedical applications calls upon the 
combination of different features in one nanocarrier for multifunctional purposes. The ideal 
vision of a nanomedicine today may include therapeutic and imaging components. This leads 
to the development of theranostics for simultaneous diagnosis and therapy. 293 Nanoparticles 
have demonstrated suitable features and properties for imaging, such as favorable 
pharmacokinetics and biodistribution behavior, diverse material composition and surface 
chemistry, regarded as flexible platforms for the addition of multiple functional ligands, such 
as targeting moieties, therapeutics, and/or contrast materials. 293-295 
Several materials can serve as contrast agents, either by directly having that property 
or upon loading or functionalization. Examples including iron oxide, quantum dots, gold 
nanoparticles, carbon nanotubes and silica/silicon nanoparticles have been reviewed 
elsewhere. 293 In particular, radiolabeling of nanoparticles seems to have gained some attention 
due to the applicability of powerful, quantitative, superior signal sensitive and enhanced 
spatial resolution imaging techniques, such as positron emission tomography (PET) and single 
photon emission computed tomography (SPECT). Nanocarrier radiolabeling can be 
accomplished in different ways, directly or indirectly, via prior functionalization, and depends 
on the type of material and radiotracer used. For example, chitosan hydrogel nanoparticles 
carrying vascular endothelial growth factor proteins or peptides were radiolabeled with 99mTc 
for targeting the ischemic myocardium and monitoring the nanoparticle’s accumulation.178 
Sarparanta et al. radiolabeled PSi particles directly with 18F for nuclear imaging with PET 
without the need for prior functionalization of the PSi surface, because of the spontaneous Si-
F bond formation. 296 Moreover, the use of 111In for PSi radiolabeling for SPECT may require 
prior surface modification with metal chelators.26 In the latter case, 1, 4, 7, 10-
tetraazacyclododecanetetraacetic acid (DOTA), known to form kinetically and 
thermodynamically stable complexes with trivalent radionuclides, was used to react with 
trivalent radionuclides, such as 111In or 67/68Ga. 297 Wang et al. made use of PSi-based 
nanomaterials, surface functionalized with DOTA and RGD targeting ligand, radiolabeled with 
111In for application in cancer theranostics, as illustrated in Figure 8.26 In this thesis, the same 
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kind of metal chelator (DOTA) was used for radiolabeling purposes in similar PSi-based 
nanoparticles. 
 
 
 
 
Figure 8. Nano-SPECT/CT fused images of the whole mouse. Images were taken in a dynamic 
mode during 1 h at 5 min post-injection and at 26 h for (A) PSi-iRGD i.v., and (B) PSi-iRGD 
intratumoral (i.t.). Copyright © 2015 Elsevier B. V. Adapted and reprinted with permission 
from ref.26. 
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3. Aims of the study 
Particulate systems have been increasingly studied for the therapy and imaging of MI 
over the last decades. The search for better and more effective therapeutic strategies for 
treating the injured heart (unable to regenerate) is urgent. In this thesis, PSi and AcDXSp-
based carriers, widely studied also for other biomedical applications, were investigated for 
their biocompatibility and targeted heart-homing and imaging potential through surface 
functionalization and labeling of the nanoparticles. In addition, heart-targeted drug delivery 
by loading of one or more therapeutic drugs is investigated. 
 
More specifically, the goals of this study were to: 
 
 
? Investigate the biocompatibility of PSi micro- and nanocarriers in heart tissue (I). 
 
? Screen the ability to specifically home cardiac cells with PSi nanocarriers by 
functionalizing them with different heart-homing peptides (II). 
 
? Reveal the mechanism of interactions of the most promising peptide-functionalized PSi 
nanosystem with cardiac cells (II, III). 
 
? Enhance the colloidal stability and blood circulation, study the biodistribution, 
intracardiac accumulation and distribution, and in vivo therapeutic effect of peptide-
functionalized PSi in heart targeting (III). 
 
? Assess whether AcDXSp-based nanosystems could be used as pH-triggered drug 
delivery carriers in direct cardiac fibroblast reprogramming (IV). 
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4. Experimental 
In this section, the experimental methods used for the studies described in the thesis are 
summarized. Experimental details can be found in the original publications (I−IV). The 
fabrication of the PSi micro- and nanomaterials was prepared by our collaborators at the 
Laboratory of Industrial Physics, Department of Physics and Astronomy, University of Turku, 
Finland. The in vivo experiments described in publication I were done by our collaborators at 
the University of Oulu. The radiolabeling of the nanoparticles, SPECT/CT, and 
autoradiography experiments were performed in collaboration with the Laboratory of 
Radiochemistry, Department of Chemistry, University of Helsinki, Finland (II, III).  
 
 4.1.   Preparation and characterization of the PSi micro- and nanoparticles and 
the AcDXSp nanoparticles 
 
4.1.1.   Production of PSi micro- and nanoparticles (I−III) 
 
   The porous structures of the PSi micro- and nanoparticles were prepared using 
electrochemical anodization.298 Multilayered free-standing PSi films were obtained from 
monocrystalline, boron-doped p-type Si ?100? wafers with a resistivity of 0.01–0.02 Ω·cm, 
using a 1:1 (v/v) hydrofluoric acid (38%)–ethanol electrolyte solution. The free-standing 
silicon films were etched using a constant etching current of 50 mA/cm2. The repeated pulse 
of low/high etching current applied led to porous films by fracturing the Si wafers. The 
multilayered porous film was lifted by elevating the current density, upon reaching the 
electropolishing region. The surface of PSi layers was stabilized by TO and THC. TOPSi was 
obtained by thermally oxidizing the multilayer films in ambient air for 2 h at 300 °C.299 THCPSi 
was obtained by at first exposing PSi films to N2 flow (1 L/min) for 30 min to remove residual 
moisture and oxygen before surface stabilization. Next, the surface was thermally 
hydrocarbonized by exposing the films to a mixture of N2/acetylene (1:1 v/v) at room 
temperature during 15 min and at 500 °C for another 15 min, then cooling back to room 
temperature under N2 flow.19 Undecylenic acid thermal addition to THCPSi was done by 
immersing the films in neat acid for 16 h at 120 °C, 247 yielding undecylenic acid thermally 
hydrocarbonized porous silicon (UnTHCPSi). As for the final particle size, nanoparticles were 
fragmented from the multilayered PSi films by a wet milling in EtOH, and the size selection 
was done using centrifugation (I−III). To produce microparticles, the anodized films were dry 
milled and the particles were separated into different size classes by sieving followed by 
centrifugation (I). 
 
 
  4.1.2.   Functionalization of UnTHCPSi nanoparticles (II, III) 
   
  The surface carboxyl groups of 3 mg of UnTHCPSi nanoparticles were activated by 1-
ethyl-3-(3-dimethylaminopropyl) carbodiimide hydrochloride/N-hydroxysulfosuccinimide 
(EDC/NHS) chemistry during 2 h at room temperature in the dark and under stirring. After, 
the excess of EDC/NHS reagents were removed and S-2-(4-aminobenzil)-1, 4, 7, 10-
tetraazacyclododecane-1,4,7,10-tetrater-butyl acetate molecules (DOTA, 150 μg/mL in 50% 
ethanol) was added to the activated UnTHCPSi nanoparticles in a ratio of 100:1 (w/w) 
(UnTHCPSi:DOTA). The obtained UnTHCPSi-DOTA nanoparticles (Un-D) were washed twice 
with 50% ethanol. The tert-butyl ester groups from DOTA were cleaved by treating the Un-D 
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nanoparticles with a standard solution of trifluoroacetic acid/triisopropylsilane/Milli-Q water 
(TFA/TIPS/H2O) in a ratio of 95:2.5:2.5 300 for 24 h at room temperature under vigorous 
stirring, after which two washing steps were done with ethanol. Three different peptides, ANP 
(United BioSystems Inc.), CSTSMLKAC (P2), and CRSWNKADNRSC (P3) (GenicBio Ltd.) 
were covalently attached to the Un-D nanoparticles. The free carboxyl groups of Un-D NPs 
were again activated for 2 h at room temperature under stirring, by using EDC/NHS chemistry. 
After removing the excess of crosslinking reagents, the peptide solutions (2 mg/mL in PBS pH 
< 7.2) were added to the activated surface of the Un-D nanoparticles in a ratio of 1:5 (Un-
D:peptide). The reaction was allowed to occur for 3 h for P2 and P3, and overnight for ANP 
under stirring at room temperature. The resultant Un-D-ANP, Un-D-P2 or Un-D-P3 
nanoparticles were washed twice with Milli-Q water (II). For publication III, the surface 
carboxyl groups of 3 mg of UnTHCPSi were first activated for 2 h with EDC/NHS chemistry, 
as described above. The activated nanoparticles were exposed to a 2 mg/mL of a 5 kDa 
heterobifunctional PEG (NH2-PEG-COOH, Jenkem Technology) in PBS (pH 7.2) in a ratio of 
1:2 w/w, (UnTHCPSi:PEG) overnight in the dark at room temperature and under stirring. 
UnTHCPSi-PEG (Un-P) nanoparticles were washed once with ethanol and twice with Milli-Q 
water. The functionalization with DOTA (yielding Un-P-D) and ANP (Un-P-D-ANP) was 
performed, as described above for publication II, except that the ratio of Un-P-D: ANP used 
was 1:5 (w/w).  
 
 
4.1.3.   Synthesis of spermine-acetalated dextran   
 
  Dextran (5 g, MW 9–11 kDa; Sigma-Aldrich) was dissolved in 20 mL of Milli-Q water. 
Sodium periodate (0.22 g; Sigma-Aldrich) was added to the dextran solution and the mixture 
was stirred at room temperature for 5 h to yield partially oxidized dextran. Upon washings and 
lyophilization, partially oxidized dextran (3 g) was modified with 2-methoxypropene (10.6 mL, 
Sigma–Aldrich) and pyridinium p-toluenesulfonate (46.8 mg; Sigma–Aldrich) in anhydrous 
dimethyl sulfoxide (30 mL, Sigma–Aldrich) during 1 h under a N2 atmosphere to obtain the 
partially oxidized AcDX. Triethylamine (TEA, 1 mL; Sigma–Aldrich) was used to quench the 
reaction and precipitate the resulting AcDX, followed by a series of centrifugations (10 min, 
68320g) and washings. The pellet was dried under vacuum at 40 °C to yield partially-oxidized 
acetalated dextran (AcDX) powder. The partially oxidized AcDX (2.0 g) was dissolved in 20 
mL of DMSO and spermine (4.0 g, 19.8 mmol; Sigma-Aldrich) was added to the solution and 
kept stirring for 24 h at 50 °C. Sodium borohydride (NaBH4, 1.0 g; Sigma-Aldrich) was added 
and the reduction reaction was allowed to occur at room temperature during at least 24 h. H2O 
(80 mL) and methanol (10 mL) were added to the flask to precipitate the polymer and to 
dissolve the excess NaBH4. Upon a series of centrifugations and washes and final 
lyophilization, the resultant AcDXSp comes as a white powder.274, 277 
 
 
4.1.4.   Preparation of spermine-acetalated dextran nanoparticles and surface   
functionalization (IV) 
 
  The AcDXSp nanoparticles were prepared by a standard single emulsion method. 
Briefly, AcDXSp polymer (6.5 mg) was dissolved in CH2Cl2 (0.125 mL). The compounds 
CHIR99021 (300 μg, Tocris) and SB431542 (500 μg, Sigma) (CRIH99021 + SB431542, CS) 
were added to the AcDXSp solution. An aqueous solution of polyvinyl alcohol (PVA, MW: 
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31000-50000 g/mol, Sigma–Adrich) (0.25 mL, 2.0%, w/v) was further added to the AcDXSp 
solution, and the mixture was mixed thoroughly and emulsified by sonication during 30 sec on 
ice, with an output setting of 5 and a duty cycle of 50%, using a probe sonicator (Sonics VCX 
750). The resulting single emulsion was transferred immediately to another solution of PVA 
(0.75 mL, 0.2% w/v) and stirred for 3 h for solvent evaporation. The resulting CS@AcDXSp 
nanoparticles were pelletized by centrifugation (16100g, 5 min) and washed twice with Lutrol® 
F127 0.5 % pH 8 (BASF) and once with Milli-Q water. All supernatants were kept for the 
detection of CHIR and SB contents by high-performance liquid chromatography (HPLC). 
Empty nanoparticles were prepared similarly. 
  The surface of the AcDXSp nanoparticles was modified with PEG (CO2H-PEG-CO2H, 2 
kDa, Sigma-Aldrich). In brief, a solution of PEG was prepared in EDC/NHS at pH 7.8. The 
EDC/NHS solution was prepared as described in section 4.1.2. This solution was added to 2 
mg AcDXSp NPs in a ratio of 10:1 (w/w) (PEG:AcDXSp). The mixture was allowed to stir at 
room temperature during 4 h in the dark, yielding AcDXSp-PEG (AcDXSp-P). For further 
functionalization with ANP, the AcDXSp-P nanoparticles were pelletized by centrifugation and 
the supernatant containing the remaining EDC, NHS, and excess of PEG was discarded. The 
AcDXSp-P nanoparticles were resuspended in a solution of ANP (pH 8, AcDXSp-P:ANP ratio 
1:1 w/w) and prepared in the same solution and kept under stirring for 3 h at room 
temperature, in the dark. The resulting AcDXSp-P-ANP nanoparticles were washed twice with 
sucrose 2% (pH 8).  
 
 
4.1.5.   Fluorescence-labeling (II−IV) 
 
   For fluorescence labeling, the Un-D (II) or Un-P-D (III) nanoparticles were activated 
using EDC/NHS chemistry and after 1 h, AlexaFluor® 488 (AF488, Life Technologies) was 
added to the reaction in a ratio of 70:1 (w/w) (nanoparticles:AF488). The reaction was allowed 
to occur for 2 h and the fluorescently labeled nanoparticles were washed with 0.05 M HCl and 
twice with Milli-Q water (II), or the excess of AF488 was simply removed by centrifugation 
before modification with ANP (III). The labeled nanoparticles were further modified with the 
respective peptides, as described in section 4.1.4.. The same treatment was applied to Un-D or 
Un-P-D particles, excluding the addition of peptides. For fluorescence labeling of AcDXSp 
nanoparticles, the AcDXSp were activated using EDC/NHS chemistry and the addition of 
AF488 was at a ratio of 500:1 (w/w) (AcDXSp:AF488) during 1 h (IV). PEGylation and 
modification with ANP were performed the same way as described in section 4.1.4.  
 
 
  4.1.6.   Physicochemical characterization (I−IV) 
 
  The hydrodynamic diameter (Z-average), PdI, and ?-potential values of the different 
nanoparticles were determined by DLS and ELS using Zetasizer Nano ZS instrument (Malvern 
Instruments Ltd). The measurements were performed in Milli-Q water and/or 5.4% glucose 
(II, III) or 2% sucrose (IV). To evaluate the morphology and size distribution of THCPSi and 
TOPSi microparticles, the samples were suspended in EtOH and a droplet of each was added 
to a metallic sample holder, allowed to dry and sputter-coated with platinum. The imaging was 
done under a scanning electron microscope (SEM; Zeiss DSM 962) (I). The size distribution 
and morphology of nanoparticles (I–IV) was evaluated by transmission electron microscopy 
(TEM; FEI Tecnai F12). The samples for TEM were prepared by embedding carbon-coated 
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copper grids into nanoparticle suspensions and allowed to dry overnight. The morphological 
features of UnTHCPSi modified nanoparticles were also imaged with a high-resolution SEM 
(ZEISS Ultra-55) (II). The evaluation of the qualitative elemental composition of UnTHCPSi, 
Un-P, Un-P-D and Un-P-D-ANP nanoparticles was done by TEM – energy-dispersive X-ray 
(EDX) spectroscopy (Hitachi S-4800 field emission scanning transmission electron 
microscope equipped with a bright field TE detector and INCA 350 EDX spectrometer) (III). 
The amount of ANP peptide covalently conjugated to the Un-D nanoparticles was determined 
by HPLC by an indirect method (II). The quantification of ANP onto Un-P-D and AcDXSp-P-
ANP nanoparticles was done by elemental analysis (EA) (Elementar Analysensysteme, GmbH), 
where the amount of peptide was calculated based on the percentage of each element (carbon 
(C), hydrogen (H), nitrogen (N) and sulfur (S)), and the chemical structure of the peptide (III, 
IV). The surface chemistry of the dry micro- and nanoparticles was evaluated by attenuated 
total reflectance Fourier transform infrared spectroscopy (ATR–FTIR), using a Bruker 
VERTEX 70 series FTIR spectrometer (Bruker Optics) and an ATR sampling accessory 
(MIRacle, Pike Technology, Inc.). The spectra were recorded in the wavenumber region of 
4000−650 cm-1 with a resolution of 4 cm-1 using OPUS 5.5 software. Finally, the colloidal 
stability of the nanoparticles was assessed by DLS. The different nanoparticles were dispersed 
in 5.4% glucose, and their Z-average, PdI and ?-potential values were measured over the course 
of 6 days. The samples were kept at +4 °C under static conditions (III). To evaluate the effect 
of human plasma (II, III) or cell medium (IV) on the size and the PdI, the nanoparticles were 
dispersed in 200 μL of Milli-Q water (II) and 5.4% glucose (III), or freshly prepared Milli-Q 
water at pH 8 (IV). Sequential samples were taken and the hydrodynamic diameter (nm), PdI 
and ?-potential values were measured at different timepoints up to 120 min (II, IV) or 240 
min (III). To evaluate the dissolution behavior of AcDXSp nanoparticles under different pH-
conditions, the AcDXSp, AcDXSp-P, and AcDXSp-P-ANP were individually added into the 
buffer solution (pH 7.4 and 5.0) at a concentration of 1 mg/mL. Samples were taken at different 
time points (100 μL) to a TEA solution (0.01%, v/v; 1 mL, pH 8) to terminate the degradation 
process of AcDXSp, centrifuged (5 min, 16100g), and again redispersed in TEA solution. The 
sample preparation for TEM imaging was similar to the process described above. 
 
 
4.1.7.   Drug loading and encapsulation, encapsulation efficiency, loading degree 
and release studies (III, IV) 
 
  In III, Un-P-D-ANP nanoparticles (1.05 mg) were suspended in 10.5 mL of a solution 
of the small molecule compound trisubstituted-3,4,5-isoxazole (C1) 301, 302 in 90% EtOH (2 
mg/mL) with stirring at room temperature for 2 h. The excess of the drug was removed by 
washing with PBS, after which 50 μg of nanoparticles were suspended in EtOH and stirred at 
room temperature for 1 h. The supernatant was collected and analyzed by HPLC for the 
detection of C1 and determination of the loading degree (LD). Drug release studies were 
conducted in human plasma for Un-P-D-ANP nanoparticles loaded with C1, as well as for the 
free C1 as a control. For that purpose, 300 μg of C1-loaded Un-P-D-ANP particles or C1 alone 
was suspended in human plasma with stirring at 37 °C and samples were collected over 4 h. 
An Agilent 1100 series HPLC system (Agilent Technologies) was used to quantify C1. A 
Gemini−NX 3 μm C18 110Å reversed phase column (100 ? 4.6 mm, Phenomenex) was used. 
The mobile phase was 0.1% phosphoric acid and MeOH (ratio of 65:35 v/v), the flow rate was 
0.8 mL/min, the injection volume was 20 μL, and the wavelength was 280 nm. To detect the 
compound in human plasma, a Zorbax C18 (4.6 × 100 mm, 5 μm) column was used as the 
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stationary phase, with the same mobile phase. The flow rate was 1 mL/min, the injection 
volume was 50 μL, and the wavelength was 280 nm. The plasma samples were diluted 1:1 with 
acetonitrile beforehand to precipitate plasma proteins. In IV, a known amount of 
CS@AcDXSp, CS@AcDXSp-P or CS@AcDXSp-P-ANP nanoparticles were suspended in 1 mL 
of acetonitrile (ACN) for total dissolution of the nanoparticles. The resulting solution and all 
supernatants were measured for the detection of CHIR99021 and SB431542 contents. The 
encapsulation efficiency (EE) and LD were calculated as follows: 
 
?????? ? ????????????????????????????????????????????????????????? ? ???? 
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  The release of CHIR99021 and SB431542 from the different nanoparticles was assessed 
at physiologically relevant pH-values of 7.4 and 5.0. The drug-loaded nanoparticles were 
immersed into the appropriate release medium, stirring at 150 rpm and 37 ± 1°C. Pure 
CHIR99021 and SB431542 were used as controls. Samples of 200 mL were taken at specific 
time points, and the same volume of fresh pre-heated buffer was added for replacement. The 
withdrawn samples were centrifuged (5 min, 16100g), and analyzed by HPLC for 
quantification of the concentrations of the drugs. The same HPLC instrument was used to 
quantify the compounds encapsulated inside the bare and functionalized AcDXSp 
nanoparticles. A Discovery® 5 μm C18 reversed phase column (100 ? 4.6 mm, Supelco) was 
used. The mobile phase was Na2HPO4:citric acid (2:1) (pH 6.0) and ACN (50:50, v/v). The flow 
rate used was 1.4 mL/min, the injection volume 5 μL, and the wavelength 274 ± 20 nm. 
 
 
4.2.   In vitro studies 
   
4.2.1. Isolation of primary cardiomyocytes and non-myocytes (I−IV) and 
continuous cell lines (II, III) 
 
  The isolation of cardiac cells from neonatal rats was adopted from Pikkarainen et al.303 
Wistar rats (1–4 days old) were euthanized by decapitation, and the cardiac ventricles were 
excised and cut into small pieces. The tissue pieces were enzymatically digested by incubating 
at 37 °C with gentle mixing for about 1:45 h in collagenase type 2 and pancreatin solution. The 
cells in suspension were collected by centrifugation. The supernatant and the top layer 
containing damaged cells were discarded, and the remaining cells were suspended in 
Dulbecco’s Modified Eagle’s Medium (DMEM)/F12 supplemented with 2.5 mM L-glutamine, 
penicillin (100 IU/mL), streptomycin (100 mg/mL) (PS, 1% v/v) and 10% heat inactivated fetal 
bovine serum (hiFBS). The cells were pre-plated for 60-80 min onto cell culture plates, and 
unattached cells (enriched cardiomyocytes)304, 305 were plated at a desired density. The day 
after plating, cardiomyocytes media was replaced by complete serum-free medium (CSFM). 
Non-myocytes were cultured in supplemented DMEM/F12 until confluency and plated for the 
experiments. The cells were maintained at 37 °C with 5% CO2 and 95% air in a humidified 
atmosphere. H9c2 (2-1) (American Type Culture Collection® CRL-1446™) myoblast cells (II) 
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were cultured in DMEM supplemented with 10% hiFBS and 1% PS. The cells were maintained 
at 37 °C with 5% CO2 and 95% air in a humidified atmosphere. 
 
4.2.2.   Chemically induced hypoxic conditions (II, III) 
   
  Healthy primary cardiomyocytes and non-myocytes were pre-treated with cobalt 
chloride (CoCl2) (II, III) at a concentration of 100 μM, 18–24 h before the experiments, in 
order to mimic the hypoxic conditions in the ischemic heart tissue.306, 307 The CoCl2 was 
maintained during the experiments. 
 
 
4.2.3.   Cytocompatibility (I–IV) 
 
  The cells were primarily seeded into 96-well plates. Primary cardiomyocytes were 
seeded at a cell density of 2−5?104 cells per well. After reaching confluency, primary non-
myocytes were seeded at a cell density of 1−3.5×104 cells per well (II–IV). H9c2 cells were 
seeded at a density of 3.5×104 cells per well and both were allowed to attach overnight (II, III). 
For publications I and II, the cell viability upon incubation with the different particles was 
assessed in 10 mM Hank's balanced salt solution (HBSS)-4-(2-hydroxyethyl)-1-
piperazineethanesulfonic acid (HEPES) buffer solution at pH 7.4. The suspensions of micro- 
and nanoparticles were prepared at concentrations ranging from 25 to 1000 mg/mL. Prior to 
the addition of the particle suspensions to the cells, the wells were washed with 100 μL of 
HBSS−HEPES (pH 7.4) buffer and 100 μL of the PSi suspensions (in HBSS−HEPES, pH 7.4) 
were added to each well. For publications III and IV, the cell viability was assessed in CSFM 
for cardiomyocytes and in DMEM/F12 (complete and serum-free (IV)) for non-myocytes. The 
cells were then incubated at 37 °C for 3 h (I), 4 h (III), 6 h (II, IV) and 24 h (III, IV). After 
the incubation, the cells were washed twice with HBSS−HEPES (pH 7.4) buffer. 50 μL of 
HBSS−HEPES (pH 7.4) and 50 μL of CellTiter Glo® (Promega Corporation) were added to each 
well. In publication IV, the cytocompatibility of cardiomyocytes and non-myocytes in complete 
medium was assessed using thyazolyl blue tetrazolium bromide (MTT). After incubation at 
37 °C for 24 h, 10 μL of MTT solution (2.5 mg/mL) were added to the cells and incubated for 
2.5 h at +37°C. The supernatant was removed and 100 μL of DMSO were added to dissolve the 
water-insoluble formazan crystals formed. Negative (1% Triton X-100), positive (cell medium) 
and blank (only Cell Titer Glo reagent® or MTT solution) controls were used and treated 
similarly. The luminescence or absorbance (490 nm) were measured using a Varioskan Flash 
Multimode Reader (Thermo Fisher Scientific). 
 
 
4.2.4.   Cell–nanoparticle interactions and displacement studies (II–IV) 
 
  The cell–nanoparticle interactions were evaluated qualitatively by TEM (II) and 
confocal microscopy (III). Quantitative cell–nanoparticle interactions were measured by flow 
cytometry (II–IV). For the TEM imaging, cardiomyocytes, non-myocytes or H9c2 cells were 
seeded onto 13 mm round shape coverslips placed on 24-well plates at a density of 105 cells per 
well and incubated with each nanoparticle’s suspension (50 mg/mL). After incubation over 6 
h, the coverslips were washed twice with HBSS−HEPES (pH 7.4) and fixed with 2.5% 
glutaraldehyde for 30 min. For TEM sample preparation, the cells were post-fixed with 1% 
osmium tetroxide in 0.1 M NaCac buffer (pH 7.4), dehydrated and embedded in epoxy resin. 
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Ultrathin sections (60 nm) were cut parallel to the coverslip, post-stained with uranyl acetate 
and lead citrate, and the images were acquired using a TEM microscope (Jeol 1400). 
  For the confocal fluorescence microscopy imaging (III), cardiomyocytes were seeded 
onto 13-mm coverslips at a density of 105 cells per well. Non-myocytes were seeded at a density 
of 4?104 cells per well in Lab-Tek 8-chamber slides. Cells were pre-treated with CoCl2 over 18–
24 h prior to and for the duration of the experiments. Both the cell types were exposed to 50 
μg/mL of AF488-labeled nanoparticles in their respective culture medium for 4 h and washed 
twice with HBSS–HEPES (pH 7.4). The plasma membrane was stained with CellMask® Deep 
Red (5 μg/mL, at 37 °C) and fixed with 4% paraformaldehyde for 20 min at room temperature. 
The coverslips containing the cardiomyocyte samples were mounted on glass slides using 
Vectashield antifade mounting medium with DAPI (Vector Laboratories). For the non-
myocytes, the nuclei were stained with DAPI-405 (2.8 μg/mL) for 5 min at room temperature. 
Leica TCS SP5II HCS A confocal inverted microscope (Leica Microsystems) was used for 
imaging. The images were processed using LAS AF (2.6.0 build 7266) software.  
  For quantitative studies (II–IV), cardiomyocytes were seeded in 6-well plates at a 
density of 4–5×105 cells per well (II, III). Non-myocytes were seeded at a density of 1–3.5×105 
cells per well (II–IV). Cells were kept under normoxic conditions (II), pre-treated with CoCl2 
over 18–24 h (II, III) or serum-starved for 18h (IV) prior to and for the duration of the 
experiments and incubated with AF488-labeled nanoparticles (50 μg/mL) for 6 h (II) and 4 h 
(III) and 1 h (25 μg/mL, IV) in the respective culture medium. For the displacement 
experiments, the cells were treated with free ANP at concentrations ranging from 1 to 100 μM, 
together with the nanoparticles (25–50 μg/mL) (II–IV). Cardiomyocytes were also pre-
treated with concentrations of anantin 308 (Bachem) ranging from 0.1–10 μM, 30 min before 
the treatment with nanoparticles. Anantin was kept during the experiments (II). The cells were 
washed, collected and suspended in HBSS−HEPES. The measurements were performed using 
an LSR II flow cytometer with a laser excitation wavelength of 488 nm. The internalization of 
nanoparticles in the ANP displacement experiments was assessed by quenching the 
fluorescence of membrane-associated nanoparticles trypan blue (0.005% v/v). Approximately 
10,000 events were obtained per sample. The data analysis was performed using FlowJo X 
10.0.7r2 software. 
 
 
4.2.5.   Immunostainings and high content cell imaging and analysis (IV) 
 
  Non-myocytes were seeded at a density of 104 cells per well in 96-well plates and starved 
during 18 h prior to the experiments. The nanoparticle suspensions or free-drugs were added 
to each well at concentrations of 1 μM of CHIR99021 and 2 μM of SB431542,123, 309 and 
incubated for 6 h. The serum-free conditions were kept during the experiments. Cells were 
washed twice with PBS and fixed with 4% paraformaldehyde for 20 min. The cells were 
permeabilized with 0.1% Triton X-100 during 10 min. The blocking step was done with 4% FBS 
in PBS for 45–60 min and incubated with primary antibodies (β-catenin, Smad3, alpha-
smooth muscle actin (α-SMA) and vimentin) for 60 min at room temperature. Secondary 
antibodies were added to each well (anti-mouse 488, anti-mouse 647, anti-rabbit 488, anti-
rabbit 647 and DAPI, and incubated for 45 min at room temperature. Cells were washed and 
stored at +4°C until imaged. The images captured using a Cellomics CellInsight high-content 
analysis platform (Thermo Scientific) with a 10x objective and analyzed simultaneously using 
a protocol based on Compartmental Analysis bioapplication. DAPI staining was used to define 
the nuclei and a 5-pixel ring around the nuclear mask was used to represent cytoplasm. 
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4.3.    In vivo studies 
 
4.3.1.   Particle injections and experimental models of MI (I–III) 
 
  About 8-week old male Sprague-Dawley rats (250–300 g) were anesthetized and 
microparticles or nanoparticles were injected intramyocardially in the LV of exposed hearts 
prior to the induction of MI, produced by ligation of the left anterior descending coronary 
artery during anesthesia.310 At one or four weeks post-infarction, echocardiographic 
measurements were performed, the rats decapitated and particular tissues were collected for 
analysis. (I) Myocardial ischemia was produced in rats by subcutaneous injection of a single 
dose of isoprenaline (5 mg/kg)311 24 h before the i.v. injection of nanoparticles. Male Wistar 
rats (233−330 g) received unlabeled and 111In-radiolabeled PSi nanoparticles i.v. via the tail 
vein. The animals were anesthetized with isoflurane (Attane Vet., ScanVet Animal Health, 
Finland) in an air/oxygen carrier at 0.4/0.6 (L/min). The animals were sacrificed at specific 
time points with an overdose of isoflurane or CO2 followed by cervical dislocation (II, III). 
 
  
4.3.2.   Echocardiographic measurements (I) 
 
  Transthoracic echocardiography was performed using the Acuson Ultrasound System 
(Sequoia™ 512) and a 15-MHz linear transducer (15L8) (Acuson, Mountain View) in 
anesthetized rats. Using two-dimensional imaging, a short axis view of the LV at the level of 
the papillary muscles was obtained and a two dimensionally guided M-mode recording 
through the anterior and posterior walls of the LV was obtained. LV end-systolic and end-
diastolic dimensions, the thickness of the interventricular septum and posterior wall were 
measured from the M-mode tracings. LV fractional shortening (FS) and ejection fraction (EF) 
were calculated from the M-mode LV dimensions. All echocardiographic measurements were 
performed by a skilled sonographer blinded to the treatments.  
 
 
4.3.3.   Hematoxylin and eosin staining and histology (I, III) 
 
  After sacrificing the animals, the hearts were removed and transverse sections of the 
middle part of the heart were fixed in 10% neutral buffered formalin for 1–2 days, embedded 
in paraffin, cut into 5 mm-sections from the injection area and mounted on slides. To evaluate 
the presence of micro-/nanoparticles and inflammatory response, formalin-fixed, paraffin-
embedded sections were deparaffinized in xylene and dehydrated in graded EtOH and stained 
with hematoxylin and eosin (H&E). Inflammation was scored from the H&E stained slides by 
evaluating the size of the inflamed granulation tissue area as either negative (−) or positive (+); 
no inflammation or very slight inflammation was scored as negative, substantial inflammation 
was scored as positive. Masson’s trichrome technique was used to define the extent of fibrosis 
(fibrotic area/total LV area) in the LV by using Nikon NISElement 3.2 software. Histological 
analysis was performed by using a light microscope (Nikon Eclipse 50i). (I) After 
autoradiography, the heart sections were subsequently stained with H&E, and a full image of 
each heart section was taken with a Nikon D40 Digital SLR camera fitted on a Nikon bright 
field microscope for digital microphotography with high color fidelity and 1? magnification 
(III). 
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4.3.4.   Gene expression analysis (I) 
 
  The total RNA from the apical heart tissue was isolated by the guanidine thiocyanate–
CsCl method.312 For quantitative real-time polymerase chain reaction (RT-PCR) analyzes, 
cDNA was synthesized from total RNA with a First-Strand cDNA Synthesis Kit (GE Healthcare 
Life Sciences) following the manufacturer’s protocol. RNA was analyzed by RT-PCR on an ABI 
7300 sequence detection system (Applied Biosystems). The results were quantified using the 
∆∆CT method and normalized to 18S housekeeping gene from the same samples to correct the 
potential variation in sample loading. 
 
 
4.3.5.   In vivo SPECT/CT imaging and ex vivo biodistribution (II, III) 
 
  Small animal SPECT/CT equipment (Bioscan NanoSPECT/CT, Mediso) was used to 
study the in vivo biodistribution and live heart accumulation of the nanoparticles. The rats 
were administered with [111In]-labeled nanoparticles intravenously, and the whole-body 
SPECT/CT images were acquired under isoflurane anesthesia immediately after injection for 
10 and 20 min (in a dynamic scanning mode with 2?10 min frames and 16 projections at 30 
sec per projection). Another scan was performed at 4 h after 111In-labeled nanoparticle 
administration (16 projections and 60 sec per projection). A 45-kV inbuilt X-ray source was 
used to acquire CT images with a 500-msec exposure time in 180 projections and a pitch of 0.5 
with an acquisition time of 5 min after the respective SPECT scan. All images were 
reconstructed using HiSPECT NG software (Scivis GmbG, Göttingen) and analyzed using 
InVivo Scope software (InviCRO LLC) (II, III). Several voxel-guided ROI were drawn from the 
apical to basal regions of the heart using the fused SPECT/CT-images, and the results were 
expressed as SUVs, which were calculated using the average radioactivity concentration of the 
ROI normalized with the injected radioactivity dose and animal weight 311 (III). After the last 
SPECT scan, the rats were sacrificed by cervical dislocation under anesthesia, and the samples 
from the blood, liver, spleen, lung, heart, kidney, bone with marrow, brain, and urine were 
collected and weighed for independent radioactivity measurements using an automated ?-
counter (Perkin Elmer Wizard 3, Perkin Elmer). The results were calculated as the percentage 
of injected dose per gram of tissue (%ID/g). 
 
 
4.3.6.   Tissue autoradiography and image quantification (III) 
 
    The fresh hearts were snap-frozen in isopentane on dry ice after being washed in PBS, 
and thin sections of 10 μm were cut from the apical, medial and basal regions using a cryostat 
microtome (CM1950, Leica Microsystems). The sections were thaw-mounted on SuperFrost 
Plus microscope slides (VWR Collection, Finland), air dried for 3−4 h and stored at −20 °C 
until autoradiography. The cryosections were exposed to a digital imaging plate (Fujifilm) for 
88 h, and the plate was scanned on a Fujifilm-5100 scanner. Images were analyzed with AIDA 
2.0 imaging software (Raytest). ROIs were drawn on the endocardium and epicardium (apical, 
medial and basal regions) autoradiographs based on the identification of their respective heart 
sections from H&E-stained photographs. 
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4.3.7.   Biological effects of drug-loaded ANP-modified nanoparticles in vivo (III) 
 
  The C1-loaded Un-P-D-ANP or unloaded Un-P-D-ANP nanoparticles were suspended 
in 5.4% glucose (500 μg/mL) and 200 μg aliquots were injected i.v. in rats with isoprenaline-
induced MI. The animals were sacrificed by either isoflurane overdose or CO2 and additional 
cervical dislocation at three different time points: 4, 24 and 72 h after the first NP injection. 
The nanoparticles were administered once in the 4-h and 24-h study groups, and three times 
(t = 0, 24 and 48 h) in the 72-h study group. Immediately after sacrifice, the hearts were 
collected and washed in PBS while still pumping. The LV was placed between two tweezer 
platforms, frozen in liquid N2 and further stored at −80 °C. The LV was cut into 100-μm slices 
from the endocardial side. The first 12 slices were combined and considered the endocardium. 
A NucleoSpin RNA Midi Kit (Macherey-Nagel) was used to isolate RNA and protein. The tissue 
samples were homogenized in lysis buffer using a Gentle MACS dissociator with M-tubes 
(Mitenyi Biotec). The proteins were isolated from RNA, precipitated using Protein Precipitator 
(Macherey-Nagel), washed with 50% ethanol, pelletized and air-dried. Finally, the protein 
pellet was dissolved in TCEP buffer (Macherey-Nagel), and the protein concentration was 
determined using a BCA protein assay kit (Pierce). Ten micrograms of total protein were 
loaded onto a 10% TGX gel (Bio Rad), separated at 160 V for 70 min and transferred to a 
nitrocellulose membrane (Bio Rad) for 7 min using the Trans-Blot Turbo Transfer System (Bio-
Rad). For membrane blocking and antibody dilutions, 5% BSA in TBS-Tween (0.1%) was used. 
The immune complexes were visualized using SuperSignal West Pico Chemiluminescent 
Substrate (ThermoFisher Scientific), and chemiluminescence was detected and digitalized 
with a Luminescent Image Analyzer LAS-3000 (Fujifilm). Two identical western blots were 
run from each sample group for detection of phosphor-ERK and total ERK 1/2, phosphor-p38 
and p38 and glyceraldehyde 3-phosphate dehydrogenase (GADPH). The immunoreactive 
bands were quantified using Quantity One software (Bio-Rad), and the optical densities were 
normalized to the reference GAPDH.  
 
 
4.4.    Statistics (I–IV) 
 
  Results are expressed as the mean ± standard deviation (SD) or standard error of the 
mean (S.E.M.). Statistical analyses were performed using a SPSS version 19.0.0.1 (SPSS Inc., 
Chicago, IL, USA) and GraphPad Prism version 5.00 (GraphPad Software, San Diego, 
California, USA) (I, III). For evaluation of the extent of inflammation and granulation tissue 
caused by the micro/nanoparticle injection, Fisher's exact test was used (I). To determine the 
statistical difference between two groups, the independent samples Student's t-test was used. 
For multiple comparisons, the statistical significance was evaluated by one-way analysis of 
variance (ANOVA), followed by a Bonferroni or Tukey-Kramer post hoc tests (I−IV). The 
probability values of *, #, §, ᴥp < 0.05, **, ##p < 0.01, and ***, §§§p < 0.001 were considered 
statistically significant. 
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4.5.     Ethics (I–IV) 
 
  In publication I, experimental protocols with animals were approved by the Animal Use 
and Care Committee of the University of Oulu and the Regional State Administrative Agency 
for Southern Finland, and conform to the Guide for the Care and Use of Laboratory Animals 
published by the US National Institutes of Health. In publications II and III, all experimental 
protocols with animals were approved by the Laboratory Animal Center of the University of 
Helsinki and the National Animal Experiment Board of Finland according to the EU’s 
Guidelines for Accommodation and Care of Animals, following the Act (497/2013) and the 
Decree (564/2013) on Animal Experimentation approved by the Finnish Ministry of 
Agriculture and Forestry, and the EU Directive (2010/63/EU). For the primary cell cultures 
for in vitro experiments in all the publications I–IV, the animals were used after an internal 
license was authorized and approved by the Laboratory Animal Centre, University of Helsinki. 
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5. Results and discussion 
 
There is a limited amount of information available showing the advantages of 
nanoparticulate systems for the treatment of cardiac ischemic disease, which requests for more 
studies in order to deliver biologicals and poorly-soluble small drug molecules that would be 
able to reverse the remodeling process, the dysfunctional fibrotic scar formation and/or 
promote cardiac regeneration after a MI event. In this thesis, the potential of PSi-based and 
AcDXSp-based nanosystems was explored. At first, the biocompatibility of PSi to cardiac cells 
and tissues was evaluated, after which a screening of different peptide-modified PSi 
nanosystems was performed to investigate the potential targetability, subsequently followed 
by an extensive in vivo study of the biodistribution, heart accumulation, selectivity to the 
ischemic heart areas and drug delivery. In the same line, AcDXSp nanoparticles were 
functionalized for enhanced stability, compatibility and targeting, and their potential to deliver 
different payloads for combined cardiac therapy in a controlled fashion was assessed. 
  
 
5.1.   Cytocompatibility and biocompatibility of PSi nanoparticles of different 
surface chemistries (I) 
The study of the biosafety of a synthetic material for a new biomedical application, such 
as drug delivery and targeting, is of utmost importance to ensure successful delivery of 
therapeutics without exerting significant deleterious effects.314-317 Because limited information 
is available about the effects of nanostructured materials on the heart tissue,318 and there is a 
lack of previous reports describing the application of PSi materials for the application in 
cardiovascular diseases, the focus of this study was to investigate the cyto- and biocompatibility 
of PSi micro- and nanoparticles of different surface chemistries in primary cardiomyocytes, as 
well as in vivo in healthy and in MI LAD rat models. 
 
 
5.1.1.   Characterization and cytocompatibility of THCPSi and TOPSi particles (I) 
 
In this initial study, a brief physicochemical characterization of the used hydrophobic 
THCPSi microparticles and hydrophilic TOPSi micro- and nanoparticles was performed, and 
their cytocompatibility assessed. Figure 9A–E shows representative SEM images of THCPSi 
and TOPSi microparticles and a representative TEM image of the TOPSi nanoparticles, 
characterized by an average particle size of 7 and 19 μm for the THCPSi microparticles, 7 and 
17 μm for the TOPSi microparticles, and 110 nm for the TOPSi nanoparticles, showing an 
irregular shape. The cytocompatibility of THCPSi and TOPSi micro- and nanoparticles was 
evaluated by incubating the micro- and nanoparticles with cardiomyocytes and measuring 
their metabolic activity. A possible reason for the TOPSi microparticle toxicity could lie in the 
differences in size, as the TOPSi microparticles induced higher toxic effect than the TOPSi 
nanoparticles. This observation is in agreement with a previous study, where TOPSi particles 
in a size range of 1–25 μm were found to induce the most toxic effects in Caco-2 and RAW 
264.7 macrophage cells, compared to TOPSi nanoparticles.299 Overall, THCPSi microparticles 
and TOPSi nanoparticles were less toxic towards the primary cardiomyocytes (Figure 9F–G). 
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Figure 9. Characterization of TOPSi and THCPSi micro- and nanoparticles and cell viability 
studies used in publication (I). (A–D) SEM images of TOPSi 7 μm (A), TOPSi 17 μm (B), 
THCPSi 7 μm (C), THCPSi 19 μm (D) and TEM image of TOPSi 110 nm nanoparticles (E) used 
in this study. Scale bars are 40 μm and 500 nm for the SEM and TEM images, respectively. (F–
G) Metabolic activity of primary cardiomyocyte cells determined by the CellTiter-Glo? 
Luminescence Cell Viability Assay after 3 h incubation at 37°C with THCPSi and TOPSi 
microparticles (F), and TOPSi nanoparticles (G). The results are expressed as mean ? S.E.M. 
(n = 3). *p<0.05, **p<0.01 and ***p<0.001 vs. control. Copyright © 2014 Elsevier B.V., 
adapted and reprinted with permission from publication (I). 
 
 
5.1.2.    Assessment of cardiac function 
 
The in vivo biocompatibility of THCPSi microparticles and TOPSi micro- and 
nanoparticles was evaluated by injecting the particles intramyocardially. To study the effects 
of THCPSi and TOPSi micro- and nanoparticles on the function of the heart, cardiac function 
was assessed using echocardiography at 7 days or 4 weeks post-injection. THCPSi (7 and 19 
μm) and TOPSi (7 and 17 μm) microparticle injections had no effect on LV systolic function 
(ejection fraction or fractional shortening) at one week or at 4 weeks compared to control 
injected animals (Figure 10A and 10B), showing a slight increase in LV ejection fraction (11%) 
and fractional shortening (13%) at one week in response to TOPSi 110 nm particles. Based on 
these observations, and to study whether the TOPSi particles can be a useful biomaterial in an 
experimental MI, LAD ligation was performed immediately after intramyocardial particle 
administration. Ligation of the LAD expectedly caused a decrease in the ejection fraction 
(Figure 10C) and fractional shortening (Figure 10D) in conjunction with the injection of 
TOPSi 7 μm during the one week’s follow-up. Other parameters in both healthy and MI 
animals, such as cardiac output, stroke volume or heart rate, were not altered in consequence 
to any of the aforementioned treatments. Overall, no major alterations occurred in cardiac 
function after administration of THCPSi or TOPSi particles in the myocardium of normal rat 
hearts. In addition, no unexpected changes were observed after myocardial treatment with the 
Results and discussion 
 
41 
 
TOPSi in functional alterations after MI in rats, suggesting that PSi-based materials can be 
used and tested further in experimental MI models. 
 
 
 
Figure 10. (A–B) Effect of intramyocardial delivery of THCPSi or TOPSi micro- and 
nanoparticles on cardiac function in normal rat heart. THCPSi and TOPSi microparticles had 
no effect on ejection fraction (A) and fractional shortening (B). The results are expressed as 
mean ± SEM (n = 3–4). *p<0.05 vs. control. (C–D) Effect of intramyocardial delivery of TOPSi 
micro- and nanoparticles on cardiac function in the rat heart after MI at one-week post-
infarction and particle treatment. (C) Ejection fraction and (D) fractional shortening 
alterations are normal for an infarcted heart. The results are expressed as mean ± S.E.M. (n = 
5–6). *p<0.05 vs. SHAM. Copyright © 2014 Elsevier B.V., adapted and reprinted with 
permission from publication (I). 
 
 
5.1.3.   Histology, inflammatory and fibrotic gene expression analyses 
 
The inflammatory response and cytokine production play significant roles after MI. 
Cytokines, such as tumor necrosis factor-? (TNF-?) and interleukin-6 (IL-6), mediate cardiac 
repair and remodeling through activating matrix metalloproteinases, type I and III collagen 
formation, integrin regulation, angiogenesis, and progenitor cell mobilization. 4, 319, 320 To 
evaluate the inflammatory and fibrotic responses on a gene level, the mRNA levels of the pro-
inflammatory cytokines IL-6 and TNF-?, and fibrosis promoting genes collagen I?1 (Col Ia1)320 
and the pro-fibrogenic extracellular matrix protein and cytokine osteopontin (OSP), 319 were 
measured in MI rat hearts one week after TOPSi micro- and nanoparticles injections. One week 
after MI, it was observed a significant increase in IL-6 (Figure 11A), collagen I?1 (Figure 
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11B) and osteopontin mRNA (Figure 11D) in the TOPSi 7 μm injected rat hearts. The same 
increasing trend was observed for IL-6, Col Ia1 and OSP gene expressions when TOPSi 110 nm 
particles were injected into rat hearts at one week after MI, although these changes were not 
statistically significant. The TNF-? mRNA levels did not differ (Figure 11C). This gene 
expression data is in agreement with the presented functional/echocardiographic data 
achieved from infarcted rat hearts (Figure 10), indicating that TOPSi micro- and 
nanoparticles can be considered a useful biomaterial for the treatment of MI in rats. 
Additionally, histological sections were prepared from the THCPSi and TOPSi micro- 
and nanoparticles injected into healthy rat hearts, stained with H&E for inflammation and with 
Masson’s trichrome for fibrosis detection. On one hand, at one week, fibrosis in the THCPSi 
and TOPSi micro-/nanoparticle -injected hearts did not differ significantly from the control 
hearts (Figure 11E). On the other hand, increased inflammation was observed in the 
myocardium after injection of THCPSi 7 μm microparticles (Figure 11F, black arrows), while 
only a minor inflammatory reaction was seen in control or THCPSi 19 μm and TOPSi-treated 
heart tissue sections. In the heart tissue sections after injections of THCPSi 7 and 19 μm, the 
particles constituted distinct zones, while only a few separate undissolved particles could be 
observed in heart sections after one-week post-injection by TOPSi 7 μm, 17 μm and 110 nm 
(Figure 11F). The surface chemistry properties of PSi particles play a key role in the resistance 
to degradation, so that hydrophilic TOPSi particles may degrade faster than corresponding 
THCPSi, which possess a hydrophobic surface.29, 247, 299 In addition, it has been described that 
the presence of proteins might accelerate the degradation of PSi particles, 321 which could also 
explain the faster degradation rate of TOPSi from the myocardium compared to the THCPSi 
microparticles. 
 
 
 
Figure 11. (A–D) The expression of inflammation related and pro-fibrotic genes in the rat 
heart after MI. TOPSi particles had no effect on gene expression alterations after MI. (A) IL-6 
mRNA levels, (B) Collagen (Col) I?1 mRNA levels, (C) TNF-? mRNA levels and (D) 
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osteopontin mRNA levels at one-week post-infarction and particle treatment. The results are 
expressed as mean ± S.E.M. (n = 5–6). *p < 0.05 and **p < 0.01 vs. SHAM. (E) Intramyocardial 
delivery of THCPSi or TOPSi micro- and nanoparticles has no significant effect on myocardial 
fibrosis at one week post-injection time point. The fibrotic area was assessed from Masson’s 
trichrome-stained LV sections from the rat heart and expressed as mean ? S.E.M. (n = 3?4). 
(F) Local THCPSi 7 μm, but not THCPSi 19 μm, TOPSi 110 nm, TOPSi 7 μm and TOPSi 17 μm 
or control treatment increased myocardial inflamed granulation tissue (arrow) in the normal 
rat heart when injected into the LV myocardium. Paraffin-embedded histological sections were 
stained with H&E to define the area of inflammation at one-week post-injection (scale bar 100 
μm). Copyright © 2014 Elsevier B.V., adapted and reprinted with permission from publication 
(I). 
 
 
5.2.     In vitro screening of heart-targeted UnTHCPSi nanoparticles (II) 
Several therapeutic strategies have been used to decrease the myocardial remodeling 
after an ischemic event. The traditional approaches include pharmacological therapy 55 and/or 
more invasive methodologies, such as resynchronization therapy biventricular pacing 322, 323 
and left ventricular assist devices,324 while newer strategies comprise of cell therapy and 
cardiac tissue engineering.325, 326 However, because the aforementioned approaches involve 
invasive administration into the damaged cardiac tissue, the employment of nanotechnology 
has been increasingly considered.10, 173 The second and third studies of this thesis envisaged to 
investigate the possibility of development of nanosystems, which could target the heart tissue, 
via i.v. administration. PSi nanoparticles were chosen for their biocompatibility and possibility 
for i.v. administration, as well as for the screening of heart-homing peptides in primary cardiac 
cells, and mechanistic studies of the cardiac cells; nanoparticle interaction studies were 
performed to select the most promising system to be investigated in vivo. 
 
 
5.2.1.   Surface functionalization of UnTHCPSi nanoparticles  
 
The functionalization of nanoparticles becomes of great importance when targeting a 
specific tissue. Thus, as an attempt to direct the PSi nanovectors to the heart, UnTHCPSi 
nanoparticles, originally with a hydrodynamic diameters of 159 ± 1 nm, PdI-values of 0.11 ± 
0.02 and ?-potential values of ?31 ± 2 mV, were used and further modified with a metal 
chelator molecule, DOTA, that allowed the addition of radiolabeling isotopes for in vivo 
imaging studies. After that, the heart homing peptides (ANP, P2, and P3) were covalently 
attached. Both modifications were performed using EDC/NHS chemical reaction. Particle sizes 
of the nanosystems were slightly increased after surface modification, as expected, and only 
slight changes in PdI-values indicated homogeneous size distributions (Table 4). The surface 
chemistry of the different peptide-modified nanoparticles was evaluated with ATR−FTIR, 
showing successful surface functionalization with the different peptides by the appearance 
(among other peaks) of amide I band at 1640 cm−1 and amide II band at 1550–1555 cm−1 
(Figure 12A), in line with the formation of amide bonds. The changes of zeta-potential values 
from negative to positive after covalent attachment of the peptides are in agreement with FTIR 
observations, due to the presence of amine groups in ANP, P2 and P3, which attributed positive 
charges to the particle surfaces (Figure 12B). The morphology of the high resolution (HR)-
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SEM and TEM microscopy were also used to evaluate the morphology of the nanosystems, 
represented in Figure 12C–D. 
 
Table 4. Hydrodynamic diameter (nm) and PdI of the PSi nanoparticles developed in II. 
Nanoparticle Size (d.nm) PdI 
Un-D 169 ± 6 0.12 ± 0.05 
Un-D-ANP 182 ± 10 0.09 ± 0.02 
Un-D-P2 178 ± 7 0.14 ± 0.02 
Un-D-P3 171 ± 11 0.13 ± 0.05 
  
 
 
 
Figure 12. Characterization of the nanoparticles used in publication (II). (A) ATR–FTIR 
spectra. Amide I and II bands at 1550–1555 cm−1 (in-plane N–H bending and C–N stretching) 
and 1640 cm−1 (C=O stretching) (bands 1 and 2) of the peptide-modified Un-D NPs. Un-D 
spectra reveal the carbonyl C=O stretching band at 1713 cm−1 (band 3). C-H stretching bands 
belonging to the long linear aliphatic chain of the undecylenic acid of the NPs at 2929 and 2855 
cm−1 for the Un-D NPs are visible (region 4) and the appearance of a third band at 2970 cm−1 
(band 5) correspond to the C-H stretching vibration bands of the amino acids’ side chains. (B) 
?-potential values of the NPs used in publication (II), mean ± s.d. (n = 3). (C) HR-SEM images 
of Un-D (i); Un-D-ANP (ii); Un-D-P2 (iii), Un-D-P3 (iv). Scale bars 100 nm. (D) TEM images 
of Un-D (v); Un-D-ANP (vi); Un-D-P2 (vii), Un-D-P3 (viii). Scale bars 500 nm. Copyright © 
2016 Elsevier B.V., reprinted with permission from publication (II). 
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5.2.2.   Cytocompatibility studies in different cardiac cell types  
 
The toxicity of nanoparticles is dependent on biological factors like cell type and 
exposure conditions, as well as on material-related variables, such as size and morphology, 
surface area, hydrophobicity, and surface charge. These factors can play a significant role in 
the reactive oxygen species-related toxicity and create potential sites of interaction with 
receptors, leading to variable degrees of cytotoxicity.19, 327 In this study (II), the 
cytocompatibility of PSi-based nanomaterials functionalized with heart-homing peptides (25, 
50, 100, and 250 μg/mL) was evaluated in primary cardiomyocytes, primary non-myocytes, 
and H9c2 cells after 6 h of incubation (Figure 13). For all the cell types tested, there was an 
increase in the nanoparticles’-induced toxicity in a concentration-dependent manner. The 
lower cell viability values were observed for the peptide-modified PSi nanoparticles because of 
their positive surface charge, in comparison with the negatively charged Un-D nanoparticles. 
The positive particles are more likely to have higher interactions with the cell membrane 
compared to nanoparticles with neutral or negative surface charge.328, 329 Cardiomyocytes 
seemed to be more sensitive to Un-D-ANP nanoparticles (Figure 13A), which could be due to 
the high number of free amine groups present in ANP peptide, and thus, the more positive 
nanoparticle. In addition, the cardiomyocytes internalized more extensively Un-D-ANP 
(Figure 14A and 14D) than Un-D-P2 or Un-D-P3. The greater cellular internalization may 
influence the cell viability, similarly as observed for other nanosystems.330-332 H9c2 cells, in 
contrast, showed to be more resistant to the presence of all the nanoparticles tested (Figure 
13C). In summary, a satisfactory cellular viability was achieved for nanoparticle 
concentrations up to 50 μg/mL, which was the concentration chosen for further cell studies. 
 
 
 
 
Figure 13. Cytotoxicity profiles of primary cardiomyocytes (A), primary non-myocytes (B), 
and H9c2 cells (C) after exposure to Un-D and peptide-functionalized Un-D NPs. The ATP-
content was measured after 6 h incubation with different concentrations of PSi nanoparticles. 
The level of significance was set at probabilities of *p < 0.05, **p < 0.01, and ***p < 0.001 vs. 
control (HBSS). Values are represented as mean ± s.d. (n ≥ 3). Copyright © 2016 Elsevier Inc., 
reprinted with permission from publication (II).  
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5.2.3.   Cell–nanoparticle interactions and mechanistic studies (II, III) 
 
The ultimate goal of the biofunctionalization of the NPs with targeting moieties is to 
ensure a more direct and specific interaction between the nanocarrier and the tissue of interest 
at the cellular level, and eventually, internalization of the nanocarrier to the cytoplasm, where 
it may release one or several therapeutic payloads. However, besides the surface chemical 
composition, there are other factors that can affect the uptake of the nanoparticles and their 
interactions with the cells. Size, shape, surface charge and hydrophobicity are some of the 
physical properties that can dictate the interactions of a nanovector with cells.333 In 
publications (II) and (III), primary cardiomyocytes and non-myocytes (mainly cardiac 
fibroblasts)3 were used to study the cell–nanoparticle interactions and their main mechanism 
in hypoxia-like conditions. To induce hypoxia, cells were pre-treated with CoCl2, a compound 
that stabilizes the hypoxia inducible transcription factor 1a. Cobalt is a metal that has the ability 
to inhibit key enzymes that participate in the oxygen dependent degradation of the 
transcription factor, thus upregulating the hypoxic signaling pathway.306, 307 Because the 
nanoparticles tested had approximately the same sizes and irregular shapes, it was 
hypothesized that most of the differences in the cell–nanoparticle interactions were probably 
explained by the different surface charge and surface chemical composition of the 
nanoparticles. 
Primarily, the screenings of the different peptide-modified nanoparticles were 
performed by incubating them with primary cardiomyocytes (Figure 14A) and non-myocytes 
(Figure 14B), using flow cytometry analysis. In both the cell cultures, the Un-D-ANP 
nanoparticles had higher cellular uptake percentages compared to the other peptide-modified 
nanoparticles. It is well-known that positively-charged nanosystems interact more readily with 
negatively charged groups on the cell surface through electrostatic interactions and translocate 
across the plasma membrane.334 Un-D-ANP nanoparticles had the most positively charged 
surface (Figure 12B). ANP is a 28 amino acids peptide that contains 5 arginines, 1 asparagine 
and 1 glutamine amino acids that possess primary amines.68 Such amine groups protonate at 
pH values lower than the isoelectric point of ANP (pH 11), which largely contribute to the 
positively charged surface of Un-D-ANP at physiological pH. Thus, Un-D-ANP could be 
unspecifically internalized due to the interaction with random negative domains of the cell 
membrane. However, to elucidate this point, it was observed that the cellular internalization 
of Un-D-ANP occurred at least in part via the NPR-A receptor, which is expressed at the cell 
membrane level both in cardiomyocytes and non-myocytes.335-337 Cardiomyocytes were pre-
treated with the NPR-A specific antagonist anantin,338, 339 which was kept during the 
incubation with Un-D-ANP nanoparticles. The inclusion of anantin showed inhibition of the 
interaction between cardiomyocytes and Un-D-ANP. This observation confirmed the 
specificity of the interaction between cardiac cells and ANP-functionalized nanosystems and 
supported the targetability role of ANP in the nanoparticles (Figure 14C). For the P2 and P3-
functionalized nanoparticles, their internalization could be due to amine groups at the surface 
of the Un-D-P2 and Un-D-P3 nanoparticles, granting them a positive charge (Figure 14B); 
however, the mechanisms by which the peptides homed in the ischemic myocardium are not 
yet fully understood.340, 341 Due to the lack of information on the binding mechanism for these 
peptides to cardiac cells, they were not tested in the competitive cellular displacement studies. 
This, in addition to the fact that ANP nanoparticles had higher interactions with cardiac cells, 
led us to further studies performed using the ANP-functionalized nanoparticles.  
In publication (III), it was again demonstrated that Un-P-D-ANP nanoparticles 
interacted to a very high extent with both cardiomyocytes and non-myocytes as compared to 
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Un-P-D nanoparticles (Figure 14D and 14F), and the addition of PEG to the formulation did 
not alter the specificity of the ANP functionalized nanoparticles. Additionally, it was observed 
a competitive interaction between Un-P-D-ANP nanoparticles and free ANP leading to 
decreased cell–nanoparticle interactions, both in cardiomyocytes and non-myocytes, in a 
concentration dependent manner (Figure 14E and 14G). This data proved the preferential 
specific interaction of the Un-P-D-ANP with membrane NPR rather than non-specific 
interactions, which is in agreement with previous observations340 and reports about ANP–NPR 
specific interactions.336 
 
 
 
Figure 14. Quantitative and mechanistic determination of the cell−nanoparticles association 
and internalization. (A–B) Cellular internalization screening of different peptide-modified Un-
D nanoparticles in (A) hypoxic cardiomyocytes and (B) non-myocytes. (C) Cardiomyocytes 
were incubated with Un-D-ANP nanoparticles + the NPR-A specific antagonist anantin (II). 
(D–G) Cellular interactions of Un-P-D and Un-P-D-ANP in (D) hypoxic cardiomyocytes and 
(F) non-myocytes. Cellular competition assay studies were performed by incubating free ANP 
and ANP-modified nanoparticles with (E) hypoxic cardiomyocytes and (G) non-myocytes 
(III). About 10,000 events were evaluated for each measurement. To determine the statistical 
difference between two groups, the independent samples Student’s t-test was used. For 
multiple comparisons, one-way ANOVA, followed by Bonferroni post hoc test was performed. 
The level of the significant differences relative to the control nanoparticles and among the 
different peptide-conjugated PSi NPs was set at probabilities of *p < 0.05, **p < 0.01, and ***p 
< 0.001. Values are represented as mean ? s.d. (n ≥ 3). Copyright © 2016 Elsevier B.V.; 
Copyright © 2017 WILEY?VCH Verlag GmbH & Co. KGaA, Weinheim. Adapted and reprinted 
with permission from publications II and III. 
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5.3.   Drug delivery with multifunctional PSi nanoparticles to the endocardial 
layer of the injured heart (III) 
After investigating the biocompatibility of PSi-based materials towards the heart tissue 
and screening different surface modifications for the enhanced specificity to cardiac cells, in 
publication (III) the most promising formulation was further evaluated in vivo. In this work, 
the heart regional accumulation and selectivity of the intravenously administered 
nanoparticles was assessed, followed by the delivery of a lead cardioprotective compound302 
(C1) and observations, if any, of relevant biological effects. 
 
 
5.3.1.   PEGylation and stability of UnTHCPSi nanoparticles 
 
In publication (III), it was developed PEGylated and indium 111In-labeled PSi 
nanoparticles functionalized with ANP to specifically target the myocardial NPRs.297, 343, 344 To 
achieve a sufficient colloidal stability and prolonged blood circulation time, the UnTHCPSi 
nanoparticles 247 were surface-functionalized with NH2-PEG-CO2H using EDC/NHS 
chemistry, to obtain PEGylated PSi (Un-P) nanoparticles. The Un-P nanoparticles were further 
modified with the trivalent metal chelator DOTA (Un-P-D) for radiolabeling and in vivo 
imaging purposes and finally functionalized with the heart targeting ANP (Un-P-D-ANP). The 
size, size distribution and charge of the nanoparticles were analyzed by DLS and ?-potential 
measurements after each modification step. For in vivo administration, the nanoparticles were 
dispersed in an isotonic solution of 5.4% glucose before and after simulated radiolabeling, and 
the physicochemical properties were comparable to those observed in Milli-Q water, as 
presented in Table 5. 
 
Table 5: Hydrodynamic diameter (nm), polydispersity index (PdI) and zeta (?)-potential 
value of the nanosystems in Milli-Q Water and in 5.4% glucose solution, at the different stages 
of development and after simulated radiolabeling. 
 
Sample 
Size (d.nm) PdI ?-potential (mV) 
Milli-Q 
water 
5.4% 
glucose 
Milli-Q 
water 
5.4% 
glucose 
Milli-Q 
water 
5.4% 
glucose 
UnTHCPSi 165 ± 3 193 ± 10 0.10 ± 0.01 0.16 ± 0.03 −32.3 ± 0.2 −26.5 ± 1.3 
Un-P 185 ± 8 205 ± 10 0.14 ± 0.04 0.13 ± 0.07 −35.7 ± 5.0 −32.1 ± 1.7 
Un-P-D 173 ± 9 202 ± 10 0.12 ± 0.02 0.10 ± 0.03 −23.0 ± 4.4 −8.5 ± 0.7 
Un-P-D-ANP 201 ± 10 229 ± 1 0.14 ± 0.02 0.15 ± 0.03 +27.3 ± 2.6 +23.1 ± 2.6 
Simulated radiolabeling 
Un-P-D 
− 
204 ± 24 
− 
0.13 ± 0.05 
− 
−34.4 ± 5.8 
Un-P-D-ANP 225 ± 4 0.35 ± 0.09 +6.2 ± 1.5 
 
A considerable improvement in the colloidal stability of the nanoparticles was observed 
after PEGylation, which is necessary to improve the blood circulation time and prevent the 
aggregation of the particles after i.v. administration, by decreasing the occurrence of protein 
opsonization.169 The colloidal stability of the multifunctional nanoparticles was screened in 
human plasma over 4 h at 37 °C for each surface modification step. The PEGylation was 
effective in stabilizing the nanoparticles, as the size of the Un-P nanoparticles remained almost 
unaltered and the PdI-values were only slightly increased over 4 h of incubation with human 
plasma when compared to UnTHCPSi nanoparticles, demonstrating the role of PEG in the 
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formulation as a stealth promoting and hydrophilic coating (Figure 15A and 15B).343 A slight 
increase in the hydrodynamic diameter and PdI were observed after DOTA and ANP additions 
to the nanoparticle’s surface, suggesting weaker stealth properties, probably caused by at least 
partial coverage of the surface PEG polymer and alteration of the surface ?-potential values of 
the nanosystems, favoring the formation of protein corona onto the nanoparticles’ surface.344 
Still, the colloidal stability in human plasma was improved compared to the bare hydrophobic 
UnTHCPSi nanoparticles, where the sudden increase in size was followed by a decrease over 
time, suggesting a possible transient protein corona formation and disaggregation of roughly 
attached proteins on the surface of the UnTHCPSi particles.346-348  
To investigate the long-term aqueous colloidal stability in the injection solution, the Un-
P-D and Un-P-D-ANP nanoparticles were suspended in 5.4% glucose, and their size and PdI 
values were measured over 6 days. The Un-P-D-ANP nanoparticles exhibited more stable size 
and PdI than the Un-P-D nanoparticles over time (Figure 15C and 15D), suggesting that the 
surface functionalization with ANP had a further stabilizing effect on the nanoparticles. 
 
 
Figure 15. Assessment of the impact of human plasma proteins on the hydrodynamic 
diameter (A) and PdI (B) of UnTHCPSi, Un-P, Un-P-D and Un-P-D-ANP nanoparticles after 
incubation for 240 min at 37 °C. Values are represented as the mean ± s.d. (n = 3). Colloidal 
stability of Un-P-D (C) and Un-P-D-ANP (D) nanoparticles in the injection buffer (5.4% 
glucose). The hydrodynamic diameter and PdI of the nanoparticle suspensions were evaluated 
every 2 days for 6 days. The nanoparticle suspensions were stored under static conditions at 
4 °C. Values are represented as the mean ± s.d. (n ≥ 2). Copyright © 2017 WILEY?VCH Verlag 
GmbH & Co. KGaA, Weinheim, adapted and reprinted with permission from publication (III). 
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5.3.2.   In vivo biodistribution and intramyocardial location 
 
To determine the targeting efficacy in vivo, the Un-P-D and Un-P-D-ANP nanoparticles 
were successfully radiolabeled with 111In (a ?-emitter with a half-life of 67.2 h). Isoprenaline (5 
mg/kg) was administered to the rats subcutaneously 24 h before nanoparticle injections to 
induce myocardial ischemia,311 followed by a dose of 4.1±0.8 MBq of either Un-P-D or Un-P-
D-ANP nanoparticles dispersed in 5.4% glucose, administered i.v. (0.5 mg/mL), detected by 
SPECT/CT scanning or autoradiography. The SPECT/CT scans were acquired for the whole 
body at 10 min, 20 min, and 4 h after the injection. SPECT/CT image quantification, 
represented as standardized uptake value (SUV), demonstrated that the Un-P-D-ANP 
nanoparticles were significantly accumulated in the heart area (p < 0.01), with the highest SUV 
at 10 and 20 min (Figure 16A and 16B). Next, the regional location of the Un-P-D-ANP 
nanoparticles was investigated, and it was observed that the ANP-functionalized nanoparticles 
exhibited higher accumulation towards the endocardial layer of the left ventricle. The 
autoradiographic quantification of the Un-P-D-ANP and Un-P-D nanoparticles and free InCl3 
in the heart cryosections showed that the ratio of activity between the endocardium and 
epicardium (Endo/Epi) was significantly higher (p < 0.01) for Un-P-D-ANP nanoparticles in 
the ischemic heart, as observed from the autoradiographs (Figures 16C and 16D). Further 
characterization of the transmural accumulation of nanoparticles demonstrated that the 
Endo/Epi ratio activity was higher (p < 0.05) for the Un-P-D-ANP nanoparticles in the apical 
and medial regions of the ischemic myocardium, as compared with the normal heart (Figure 
16E). These results indicated that the Un-P-D-ANP nanoparticles were predominantly homed 
to the most vulnerable region of the heart after an ischemic event, the endocardial layer, likely 
due to the increase in NPR expression.71, 349 To confirm the presence of the nanoparticles in the 
endocardial region of the heart, thin sections of regions of interest (ROI) were imaged by TEM 
and energy-dispersive X-ray (TEM−EDX). The images demonstrated the presence of the 
nanoparticles inside the cells 10 min after i.v. administration (Figure 16F). The identification 
of atomic elements by TEM−EDX showed the presence of silicon (Si) (Figure 16G), 
confirming the presence of PSi nanoparticles in the endocardial layer of ischemic hearts.  
 
 
 
 
Results and discussion 
 
51 
 
 
Figure 16. In vivo assessment of the accumulation, specificity and regional location of the 
nanoparticles in the infarcted myocardium after systemic administration in rats. (A) 
SPECT/CT image quantification of the SUVs in the rat heart at 10 min, 20 min, and 4 h after 
i.v. administration of the nanoparticles. (B) Representative sagittal SPECT/CT images showing 
the biodistribution of the nanoparticles at 10 min after i.v. administration. Arrows indicate the 
location of the heart. (C) Representative H&E stainings and autoradiograms of apical, basal 
and medial rat heart sections (from a single heart for each treatment: Un-P-D-ANP, Un-P-D, 
and 111InCl3 control), showing the localization of radioactivity 10 min after the injection of 
nanoparticles or 111InCl3. Delineated regions 1 and 2 represent examples of the regions of 
interest (ROI) used for activity quantifications. (D) Autoradiographic quantification of 
radioactivity in the endocardium (Endo) and epicardium (Epi) for Un-P-D-ANP, Un-P-D 
nanoparticles, and 111InCl3 presented as a ratio of Endo to Epi. The results are shown for the 
whole heart 10 min and 4 h after the injection of nanoparticles into rats with isoprenaline-
induced MI. (E) Autoradiographic quantification of the radioactivity in the Endo and Epi 
regions of the heart in the apical, medial and basal sections in isoprenaline-induced MI and 
normal rat groups, presented as a ratio of Endo to Epi. (F) Representative TEM image of a Un-
P-D-ANP nanoparticle in the endocardial region of a heart section. (G) Elemental composition 
of the selected area (F, red box) by EDX analysis showing the presence of the Si element (red 
arrow). Copyright © 2017 WILEY?VCH Verlag GmbH & Co. KGaA, Weinheim, reprinted with 
permission from publication (III) 
 
 
5.3.3.   Drug loading, release, and in vivo modulation of hypertrophic signaling 
 
To demonstrate the therapeutic potential of the Un-P-D-ANP nanoparticles towards 
the infarcted myocardium, the trisubstituted-3,4,5-isoxazole (C1)301, 302 was loaded into the 
ANP-modified nanoparticles. The administration of C1 (30 mg/kg, intraperitoneally) in MI 
models (mice and rats with angiotensin II-mediated hypertension) significantly increased the 
left ventricular ejection fraction and fractional shortening.301, 302 The loading degree of C1 in 
the Un-P-D-ANP nanoparticles was 16±5%. Figure 17A shows the release profile of C1 in 
human plasma. It was observed an improvement in the dissolution profile of C1 when 
compared with the drug alone (approximately 0.12% in the time-frame shown), as C1 is poorly 
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water-soluble, suggesting that the Un-P-D-ANP may act as a beneficial drug carrier for the 
delivery of this compound. Thus, isoprenaline-induced myocardial ischemia rats were 
administered i.v. with unloaded and C1-loaded Un-P-D-ANP nanoparticles, and the effect on 
MAPK signaling was assessed in the endocardial layer of the left ventricle, at 4 h, 1 day (groups 
receiving one single dose of nanoparticles) and 3 days (groups received three doses of unloaded 
or C1-loaded Un-P-D-ANP nanoparticles at 0 h, 24 h, and 48 h, and were sacrificed at 72 h). 
Each animal received a dose of about 31.5 μg of C1 per injection.  
Almost all the MAPK signaling components are activated in the end-stage human heart 
failure and in animal models of pathologic cardiac hypertrophy.57, 58, 350, 351 Regarding one of 
these components, ERK 1/2 is characterized by phosphorylation of the ERK 1/2 proteins, 
which will lead to the activation of hypertrophy-related transcription factors in the nucleus. 
Previous studies showed that the ERK cascade plays an essential role in signaling mechanisms 
leading to cardiac hypertrophy, and thus, the inhibition of ERK1/2 in patients with severe 
myocardial remodeling and restrictive cardiomyopathy may serve as a therapeutic choice.58, 351 
The administration of C1-loaded Un-P-D-ANP nanoparticles significantly decreased (p < 0.01) 
ERK1/2 phosphorylation, particularly after repeated administration (Figure 17B and 17c). 
The observed result suggests that the attenuation of ERK signaling cascade may lead to a 
therapeutic cardioprotective effect for the C1-loaded nanoparticles. The observed results 
suggest that the Un-P-D-ANP nanoparticles could be considered to precisely deliver relevant 
cargos and exert a protective effect in the endocardial layer of the ischemic heart. 
 
 
Figure 17. In vivo modulation of ERK1/2 MAPK signaling pathways in the endocardium after 
systemic administration of C1-loaded Un-P-D-ANP. (A) Release profiles of compound C1 in 
human plasma over 4 h. The data represent the mean ± s.d. (n = 3). (B) Western blots showing 
the total ERK1/2 and phosphorylated ERK1/2 (pERK1/2) immunoreactive bands with the 
corresponding GAPDH immunoreactive bands (U, unloaded nanoparticles; C, C1-loaded 
nanoparticles). (C) The ratio of the GAPDH-normalized optical densities for pERK and ERK in 
the endocardium of the left ventricle after i.v. administration of unloaded (U) or C1-loaded (C) 
Un-P-D-ANP nanoparticles in an isoprenaline-induced rat model of MI. The results are 
expressed as the mean ± S.E.M. (independent samples analyzed by the Student t-test set at 
probabilities of *p < 0.05 and **p < 0.01). Copyright © 2017 WILEY?VCH Verlag GmbH & Co. 
KGaA, Weinheim, adapted and reprinted with permission from publication (III) 
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5.4. Dual drug delivery using pH-responsive spermine-acetalated dextran-
based nanoparticles (IV) 
In order to have an even more versatile nanosystem that would allow a precise delivery 
of cargos into the target cells, AcDXSp was used as a core material and was further 
functionalized for improvements in biocompatibility, stability, and specificity. AcDXSp 
presents pH-dependent degradation in physiologically relevant mildly acidic conditions, which 
is ideal for intracellular delivery of cargos.31 In addition, the application of AcDX-based 
microparticles showed encouraging results for protein delivery to the ischemic heart, however 
with the drawback of invasive intramyocardial administration.182, 183 The use of small drug 
molecules for cardiac reprogramming is an emerging field, and efforts towards clinical 
translation are still limited or even inexistent.130, 352 Encapsulation of these compounds into 
particulate systems has not been addressed before for application in the direct cellular 
reprogramming of cardiac fibroblasts. Thus, in this thesis, AcDXSp was evaluated as a 
candidate for pH-triggered dual-drug delivery of relevant small molecules, CHIR99021 and 
SB431542, as previously described for direct fibroblast reprogramming into cardiomyocytes.123 
 
 
5.4.1.   pH-dependent dual drug release  
 
To evaluate the pH-dependent release from AcDXSp-based nanoparticles, dissolution 
studies were performed at relevant physiological extracellular (pH 7.4) and intracellular (pH 
5) environments, and the free drugs were used as controls. The release of the different cargos 
at pH 5 occurred fast due to the hydrolysis of the acetal groups, while at pH 7.4 the release was 
hampered by the slow degradation rate of the acetal groups present in the polymer (Figure 
18). While the free compounds demonstrated pH-dependent dissolution profiles, their release 
profiles in both conditions were similar and dictated by the degradation hydrolysis of the 
polymeric matrix towards mildly acidic conditions.353 As a consequence, a considerable 
amount of both the cargos were rapidly released in the first hour at pH 5. The dissolution rate 
of both drugs was, therefore, improved under mildly acidic conditions and precisely triggered 
only upon acidic pH stimulus, as previously described.258 The small amounts of cargos released 
at pH 7.4 are justifiable by a slight degradation of dextran at this pH resulting in the release of 
a small percentage of the cargos, as previously reported.354 Also, the surface functionalization 
of the nanoparticles made the surfaces more hydrophilic, facilitating the interaction with the 
solvent molecules and released the cargos entrapped closer to the surface, hence slightly higher 
release was observed for the functionalized nanoparticles at this pH. The degree of acetalation 
obtained for this polymer was 46.1% by 1H NMR, which also influenced the hydrolysis rate of 
the polymer, and thus, the release of cargos at pH values close to neutrality.182 Considering 
nanoparticles for intravenous administration, this is an optimal condition, since the cargo will 
only be released upon internalization into acidic subcellular compartments in the cells of the 
target tissue. In addition, the ischemic myocardium presents inflammation and consequently 
changes in the interstitial pH to 6 – 6.5,355, 356 which makes this material highly suitable for 
sustained drug delivery to the injured myocardium.182, 183  
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Figure 18. Drug release profiles of CHIR99021 and SB431542 in simulated extracellular (pH 
7.4) and intracellular (pH 5) conditions. (A–B) The release profiles of CHIR99021 and (C–D) 
SB431542 from bare CS@AcDXSp and functionalized CS@AcDXSp-P and AcDXSp-P-ANP 
evaluated at pH 7.4 and 5.0, at 37 °C. Data represent mean ± s.d. (n ≥ 3). 
 
 
5.4.2. In vitro modulation of β-catenin and Smad3 for direct fibroblast 
reprogramming 
 
In order to investigate whether the AcDXSp-based nanoparticles could be used for 
direct fibroblast reprogramming, CS@AcDXSp, CS@AcDXSp-P and CS@AcDXSp-P-ANP, and 
respective controls were incubated with non-myocytes for 6 h. The biological effect was 
assessed by quantifying the staining intensity for ?-catenin and Smad3. The cells were 
immunostained for nuclei (DAPI), ?-catenin or Smad3, and in addition, for a fibroblast 
marker, vimentin or α-smooth muscle actin (SMA), which demonstrated that the majority of 
cardiac non-myocytes were (myo)fibroblasts (Figure 19A and 19E). As controls, both vehicle-
loaded nanoparticles and the free compounds were used. In all the conditions where the 
compounds were present, 1 μM of CHIR99021 and 2.1 μM of SB431542 were used in all the 
tests, correspondent to a safe dose of nanoparticles given, which was calculated based on the 
LD of the different nanoparticles.  
The nanoparticles loaded with the Wnt activator CHIR99021 successfully stabilized β-
catenin in the cytoplasm, which in turn translocated to the nucleus the drug-loaded 
nanoparticles compared to the untreated group and the vehicle-loaded nanoparticles (p < 
0.05) (Figure 19B and 19C). Importantly, the effect of CHIR90221 on stabilization of β-
catenin in the cytoplasm was significantly higher for CS@AcDXSp-P-ANP compared with the 
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free drug (p < 0.05), indicating improvement in the delivery of CHIR99021 by the ANP-
functionalized nanoparticles. The nucleus to cytoplasm ratio of β-catenin did not differ 
significantly among groups, except for the CS group, in which to the cytoplasmic β-catenin 
appeared to be lower than in the drug-loaded nanoparticle groups. (Figure 19D).  
Furthermore, the delivery of the TGF-β inhibitor SB431542 affected the intracellular 
Smad3 by preventing its translocation to the nucleus, while it did not seem to interfere with 
the amount of Smad3 already existent in the nucleus for the 6 h (Figure 19F). Instead, the 
SB431542 prevented the phosphorylation of Smad3 by the ALK and the consequent Smad 
complex formation for nuclear translocation, which is in agreement with the mechanism of 
action of the compound.309 Although free SB431542 significantly increased the cytoplasmic 
Smad3 compared to its control (p < 0.05, CS vs. DMSO), this effect was more marked for the 
drug-loaded nanoparticles, as reflected by the statistically significant cytoplasmic increase of 
Smad3 compared to all the other groups, including the CS group (Figure 19G, p < 0.05), 
which was also noted in the ratio of nuclear/cytoplasmic Smad3 staining intensity (Figure 
19H).  
The use of nanoparticulate systems for drug delivery applications has shown numerous 
advantages in multidisciplinary biomedical fields. Delivery of small molecules, growth factors 
and nucleic acid cargos to the heart with the particulate systems using diverse strategies have 
been described.182, 191, 205, 357-362 However, employment of particulate systems for the application 
of direct cardiac reprogramming is scarce and involves generally the delivery of microRNAs 
and viral vectors.363, 364 Pharmacological induction of fibroblast reprogramming is an 
unexplored field in terms of the application of particulate carriers.130, 352 Due to the poor 
physicochemical properties of small molecules like CHIR99021 and SB431542, in this thesis 
the beneficial properties of nanoparticulate systems to improve the delivery of these 
compounds was explored, and at the same time to overcome the drawbacks of reprogramming 
techniques using multiple genetic factors with low efficiency, technical and safety issues.128, 365-
371  Several reports on the combined application of CHIR99021 and SB431542 for cardiac 
fibroblasts reprogramming specifically justified the concomitant use of both the compounds in 
this study to be delivered simultaneously by a functional nanoparticulate system.123, 372, 373 
Moreover, this functional nanosystem could potentially be explored for induction of 
cardiomyocyte proliferation as well, since the inhibition of GSK-3 (involved in degradation of 
β-catenin) may induce cell proliferation and mitosis in cardiomyocytes.374 As a proof-of-
concept and for the first time, we have described the development of a biocompatible and 
functional nanodelivery system for pH-triggered delivery of at least two poorly-water soluble 
small drug molecules for applications promoting cardiac regeneration. This may be extended 
to other nanoparticulate-based systems and other small drug molecules. 
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Figure 19. High-content cell imaging and quantification for the sub-cellular localization of β-
catenin. (A, E) Representative images of non-myocyte cells treated with CS@AcDXSp-P-ANP 
at the dose of 1 μM of CHIR 99021 and 2.1 μM of SB 431542, and stained for nuclei (DAPI, 
blue), β-catenin or Smad3 (green) and the fibroblast marker α-smooth muscle actin (α-SMA) 
or vimentin (red), with a 20? magnification objective (scale bars are 50 μm). (B-D) 
Quantification of β-catenin and (F-H) Smad3 staining intensity: the average intensity of (B) ?-
catenin or (F) Smad3 staining in the nucleus, (C) ?-catenin or (G) Smad3 in the cytoplasm and 
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the ratio of (D) ?-catenin or (H) Smad3 in nucleus/cytoplasm. The different treatment 
conditions are stated below each bar. Fluorescence intensity in the cytoplasm was quantified 
from a 5-pixel ring immediately outside the nucleus defined by DAPI staining, as indicated in 
panels A and E. A one-way ANOVA followed by a Tukey-Kramer post hoc test was used for the 
statistical analysis. The significance levels of the differences were set at probabilities of *p < 
0.05 for comparison with the untreated group; #p < 0.05 for comparison between loaded 
nanoparticles vs. their vehicle-loaded counterparts; §p < 0.05 for comparison between DMSO 
and CS groups and ᴥp < 0.05 for comparison of loaded nanoparticles vs. CS group. Values 
represent the mean ± s.d. (n = 3). All the results were normalized to the untreated control. 
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6. Summary and conclusions 
The investigation of regenerative and protective proposed therapeutic approaches 
including stem cell therapy, biomaterial-based therapy or the development of gene-based and 
pharmacological agents do not yet tackle the urgent medical need of successfully treating MI 
patients. Accordingly, in this thesis, PSi-based and AcDXSp-based carriers were developed as 
a base for potential applications in imaging and therapy of MI, due to their intrinsic properties 
of small size, enhanced and pH-dependent dissolution rate of poorly-water soluble cargos, 
possibility for functionalization, and biocompatibility.  
Firstly, the biocompatibility of PSi-based carriers was assessed in heart. Different sizes 
and surface chemistries of PSi were evaluated, showing that the hydrophobic THCPSi 
microparticles and TOPSi nanoparticles displayed better cytocompatibility in vitro. In vivo, 
although the THCPSi microparticles activated inflammatory and fibrotic-promoting genes, 
both micro- and nanoparticles showed no toxicity or impairment in cardiac function in healthy 
or MI rats, suggesting that the PSi materials could be a platform considered for application in 
the therapy of heart diseases. Secondly, PSi-based nanosystems were successfully 
functionalized with DOTA and 3 different peptides, for the screening of the most promising 
nanosystem towards targeted drug delivery and imaging. Cytocompatibility was achieved for 
nanoparticle concentrations up to 50 μg/mL. Further investigation of the cell–nanoparticle 
interactions in cardiomyocytes and non-myocytes revealed a preferential cellular interaction 
with ANP-functionalized nanoparticles in both the cell types. Displacement studies revealed 
that the ANP-functionalized PSi nanoparticles interacted with the cardiomyocytes 
preferentially through the NPRs present at the cell surface. These observations led to further 
investigations in the third study of this thesis with ANP-functionalized PSi nanoparticles, 
where the receptor-mediated interaction was confirmed for cardiomyocytes and disclosed for 
non-myocytes. Furthermore, improvement of the colloidal stability of the nanosystem was 
achieved upon successful PEGylation of the surface of the PSi nanoparticles. The Un-P-D-ANP 
showed good colloidal stability in both human plasma and the injection solution, 5.4% glucose. 
Radiolabeled [111In]Un-P-D-ANP nanoparticles were administered to isoprenaline-treated MI 
rats, showing not only preferential accumulation of the nanoparticles in the heart by 
SPECT/CT imaging, but also regional accumulation in the endocardial layer of the MI hearts, 
as well as selectivity towards the MI induced hearts compared with healthy hearts. The 
administration of Un-P-D-ANP nanoparticles loaded with a cardioprotective small molecule 
(C1) significantly decreased ERK1/2 phosphorylation, particularly after repeated 
administration. These observations suggested that the Un-P-D-ANP loaded nanoparticles may 
have potential therapeutic effects by delivering a poorly water-soluble cardioprotective small 
molecule to attenuate the ERK signaling cascade, which has implications in the hypertrophy 
signaling and may promote a cardioprotective effect. Finally, in the last study, AcDXSp-
functionalized nanoparticles were developed, showing pH-dependent drug delivery of two 
poorly water-soluble cargos, triggered under physiologically relevant mildly acidic pH 
conditions. In addition, in vitro drug delivery by the AcDXSp-P-ANP nanoparticles 
demonstrated superior therapeutic modulation of key signaling pathways involved in the direct 
fibroblast reprogramming into cardiomyocytes. The observation of dual therapeutic effect 
strengthens the suitability of this nanosystem for potential application in cardiac regeneration.  
 Overall, as a proof-of-concept, PSi and AcDXSp-based particulate systems were 
developed in this thesis by functionalizing their surface with stabilizing and targeting 
excipients, for improved and pH-triggered drug delivery of relevant poorly water-soluble 
cargos for the applications in MI imaging and cardioprotective and cardio restorative therapy. 
The work described here does not show optimal in vivo accumulation of PSi-functionalized 
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nanoparticles, nor represents an exhaustive study of the nanoparticulate systems developed 
regarding profound toxicologic assessment in different cell lines, bioeffects of the nanoystems 
themselves, or in vivo functional outcomes. Continuation of this work would cover the referred 
topics. Regarding dextran nanoparticle technology, further studies would involve investigation 
of the in vitro and in vivo potential applications in the direct cellular reprogramming of 
fibroblasts, as well as evaluation of functional outcomes upon MI treatment with dual-loaded 
dextran nanoparticles, as well as exploring the possibility of rescue existing cardiomyocytes 
back to the cell cycle and induce their proliferation with the same AcDXSp-based 
nanoparticles.  
The search for the perfect “nanobullet” demands continuous research in the 
development of more stable, able to comply with biological barriers, and efficient nanocarriers 
for targeted drug delivery to the heart. Although new insights on the pathological features of 
MI provide a better understanding of the existent and possibly new therapeutic targets, there 
is still lack of a specific cardiac marker(s) suitable for targeting, which puts the targetability of 
cardiac tissue into perspective. From the material point-of-view, the increasing information 
about the particularities, versatility, and advantages of nanomaterials offers a panoply of 
opportunities for the development of adaptable tools to fight MI. Yet, limitations include the 
ability to overcome biological barriers, time-consuming and complex functionalization, 
reproducibility and scalability, factors taken into account in the clinical development and 
commercialization, which may impair their translation into the clinic. Despite a large body of 
work needed, and to put the developed work into context, this thesis contributes to enrich the 
knowledge regarding PSi and dextran-based nanoparticle technology as a starting point for the 
application in MI therapy. 
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